MIRA INFORM REPORT

 

 

Report Date :

12.11.2011

 

IDENTIFICATION DETAILS

 

Name :

HOVID BERHAD

 

 

Registered Office :

121, Jalan Kuala Kangsar Ipoh Perak, 30010

 

 

Country :

Malaysia

 

 

Financials (as on) :

30.06.2011

 

 

Year of Establishment :

1945

 

 

Legal Form :

Public Independent

 

 

Line of Business :

Manufacture of pharmaceutical preparations

 

RATING & COMMENTS

 

MIRA’s Rating :

B

 

RATING

STATUS

PROPOSED CREDIT LINE

26-40

B

Capability to overcome financial difficulties seems comparatively below average.

Small

 

Status :

Moderate

 

 

Payment Behaviour :

Unknown

 

 

Litigation :

Clear

 

NOTES :

Any query related to this report can be made on e-mail: infodept@mirainform.com while quoting report number, name and date.

 

 

ECGC Country Risk Classification List – September 30, 2011

 

Country Name

Previous Rating

(30.06.2011)

Current Rating

(30.09.2011)

Malaysia

A2

A2

 

Risk Category

ECGC Classification

Insignificant

 

A1

Low

 

A2

Moderate

 

B1

High

 

B2

Very High

 

C1

Restricted

 

C2

Off-credit

 

D

 

Company name and address

 

Top of Form

Bottom of Form

Hovid Berhad

                                                                                                                                                

 

121, Jalan Kuala Kangsar

Ipoh

 

Perak, 30010

Malaysia

 

Tel:

60-5-5060690

Fax:

60-5-5061215

 

www.hovid.com

 

Employees:

1,103

Company Type:

Public Independent

Traded:

Bursa Malaysia:

HOVID

Incorporation Date:

1945

Auditor:

KPMG LLP

Financials in:

USD (mill)

 

 

Fiscal Year End:

30-Jun-2011

Reporting Currency:

Malaysian Ringgit

Annual Sales:

49.7  1

Net Income:

(1.8)

Total Assets:

66.5  2

Market Value:

52.2

 

(28-Oct-2011)

                                      

Business Description       

 

Hovid Berhad is a Malaysia-based company engaged in the manufacture of pharmaceutical and herbal products. The Company operates in two segments: pharmaceutical, which is engaged in the manufacture and sale of pharmaceutical products, and phytonutrient, which is engaged in the extraction and processing of nutrients from palm oil for the purpose of manufacturing and producing of pharmaceutical, phytonutrient and oleochemicals/biodiesel products. It has in its portfolio over 300 different kinds of pharmaceutical products, supplements, as well as tocotreienols and herbal tea. During the fiscal year ended June 30, 2010, the Company had 19 subsidiaries. On June 1, 2010, the Company completed the acquisition of 51% equity interest in Biodeal Pharmaceuticals Private Limited. For the six months ended 31 December 2010, Hovid Berhad's revenues decreased 52% to RM81.6M. Net loss totaled RM3.9M, vs. an income of RM7.5K. Revenues reflect a significant decrease in income from Carotech segment due to the lack of working capital. Net loss also reflects a decrease in gross profit margin arising from lower margin products. Hovid Berhad is into pharmaceutical business. The Company is listed in Malaysian Stock exchange.

 

 

          

Industry                                                                                                                               

 

Industry

Biotechnology and Drugs

ANZSIC 2006:

1841 - Human Pharmaceutical and Medicinal Product Manufacturing

NACE 2002:

2442 - Manufacture of pharmaceutical preparations

NAICS 2002:

325412 - Pharmaceutical Preparation Manufacturing

UK SIC 2003:

24421 - Manufacture of medicaments

US SIC 1987:

2834 - Pharmaceutical Preparations

 

 Key Executives          

   

 

Name

Title

Sue San Ho

Executive Chairman of the Board, Managing Director

Tian Hock Goh

Company Secretary

David Ho

Managing Director

Charles Lee

International Marketing & Distribution Director

Ah Ling Leong

Purchasing Manager

    

Significant Developments                                                                                                                

 

Topic

#*

Most Recent Headline

Date

General Reorganization

1

Hovid Berhad Announces Striking Off Of Ho Yan Hor (S) Pte. Ltd.

20-Oct-2011

Business Deals

1

Hovid Berhad Announces Manufacture And Supply Agreement

12-Jan-2011

Equity Investments

1

Hovid Berhad Announces Ownership Interest Of Ho Sue San @ David Ho Sue San

18-Mar-2011

Dividends

1

Hovid Berhad Announces Proposed Dividend-In-Specie

15-Aug-2011

* number of significant developments within the last 12 months

 

             

News      

 

Title

Date

Australia: Hovid Berhad Receives Patent for 'An effective pharmaceutical carrier for poorly bioavailable drugs'
Australian Government (108 Words)

24-Aug-2011

Hovid investors to get Carotech shares
Business Times (Malaysia) (44 Words)

16-Aug-2011

Key investments
The Straits Times (182 Words)

12-Jan-2011

    

Financial Summary                                                                                                                         

 

As of 30-Jun-2011

Key Ratios

Company

Industry

Current Ratio (MRQ)

1.00

2.09

Quick Ratio (MRQ)

0.67

1.48

Debt to Equity (MRQ)

0.51

0.43

Sales 5 Year Growth

0.92

4.13

Net Profit Margin (TTM) %

-3.72

17.06

Return on Assets (TTM) %

-1.51

9.59

Return on Equity (TTM) %

-5.68

18.98

 

 

 

   Stock Snapshot                                  

 

Traded: Bursa Malaysia: HOVID

 

As of 28-Oct-2011

   Financials in: MYR

Recent Price

0.21

 

EPS

-0.0074

52 Week High

0.28

 

Price/Sales

1.04

52 Week Low

0.12

 

Price/Book

1.66

Avg. Volume (mil)

0.90

 

Beta

1.15

Market Value (mil)

160.04

 

 

 

 

Price % Change

Rel S&P 500%

4 Week

7.69%

0.81%

13 Week

-12.50%

-8.54%

52 Week

13.51%

14.87%

Year to Date

16.67%

19.59%

 

 

 

1 - Profit & Loss Item Exchange Rate: USD 1 = MYR 3.084602
2 - Balance Sheet Item Exchange Rate: USD 1 = MYR 3.0195

 

 

Corporate Overview

 

Location
121, Jalan Kuala Kangsar
Ipoh
Perak, 30010
Malaysia

 

Tel:

60-5-5060690

Fax:

60-5-5061215

 

www.hovid.com

Quote Symbol - Exchange

HOVID - Bursa Malaysia

Sales MYR(mil):

153.5

Assets MYR(mil):

200.8

Employees:

1,103

Fiscal Year End:

30-Jun-2011

 

Industry:

Biotechnology and Drugs

Incorporation Date:

1945

Company Type:

Public Independent

Quoted Status:

Quoted

Previous Name:

Hovid Sdn Bhd

 

Executive Chairman of the Board, Managing Director:

Sue San Ho

 

Company Web Links

Company Contact/E-mail

Corporate History/Profile

Employment Opportunities

 

Executives

Home Page

Investor Relations

 

Products/Services

Contents

Industry Codes

Business Description

Financial Data

Market Data

Shareholders

Subsidiaries

Key Corporate Relationships

Industry Codes

 

ANZSIC 2006 Codes:

1841

-

Human Pharmaceutical and Medicinal Product Manufacturing

1199

-

Other Food Product Manufacturing Not Elsewhere Classified

 

NACE 2002 Codes:

1589

-

Manufacture of other food products not elsewhere classified

2442

-

Manufacture of pharmaceutical preparations

 

NAICS 2002 Codes:

311999

-

All Other Miscellaneous Food Manufacturing

325412

-

Pharmaceutical Preparation Manufacturing

325414

-

Biological Product (except Diagnostic) Manufacturing

 

US SIC 1987:

2834

-

Pharmaceutical Preparations

2099

-

Food Preparations, Not Elsewhere Classified

2836

-

Biological Products, Except Diagnostic Substances

 

UK SIC 2003:

2442

-

Manufacture of pharmaceutical preparations

24421

-

Manufacture of medicaments

1589

-

Manufacture of other food products not elsewhere classified

 

 

Business Description

Hovid Berhad is a Malaysia-based company engaged in the manufacture of pharmaceutical and herbal products. The Company operates in two segments: pharmaceutical, which is engaged in the manufacture and sale of pharmaceutical products, and phytonutrient, which is engaged in the extraction and processing of nutrients from palm oil for the purpose of manufacturing and producing of pharmaceutical, phytonutrient and oleochemicals/biodiesel products. It has in its portfolio over 300 different kinds of pharmaceutical products, supplements, as well as tocotreienols and herbal tea. During the fiscal year ended June 30, 2010, the Company had 19 subsidiaries. On June 1, 2010, the Company completed the acquisition of 51% equity interest in Biodeal Pharmaceuticals Private Limited. For the six months ended 31 December 2010, Hovid Berhad's revenues decreased 52% to RM81.6M. Net loss totaled RM3.9M, vs. an income of RM7.5K. Revenues reflect a significant decrease in income from Carotech segment due to the lack of working capital. Net loss also reflects a decrease in gross profit margin arising from lower margin products. Hovid Berhad is into pharmaceutical business. The Company is listed in Malaysian Stock exchange.

 

 

More Business Descriptions

Production of pharmaceuticals and herbal remedies

 

Hovid Bhd is primarily engaged in production of medicinally active substances to be used for their pharmacological properties in the manufacture of medicaments; and processing of blood. This class also includes: manufacture of chemically pure sugars; and processing of glands and manufacture of extracts of glands, etc.

 

Hovid Group (Malaysia) pharmaceutical division manufactures and markets more than 300 different types of ethical drugs, health and dietary supplements. Hovid's product categories are divided into pharmaceutical ethical, dietary supplements, injections and consumer products. Hovid has its products distributed in over 40 countries around the world.

 

 

 

 

 

 

 

 

Financial Data

 

Financials in:

MYR(mil)

 

Revenue:

153.5

Net Income:

-5.6

Assets:

200.8

Long Term Debt:

10.6

 

Total Liabilities:

104.3

 

Working Capital:

0.0

 

 

 

Date of Financial Data:

30-Jun-2011

 

1 Year Growth

-58.0%

NA

-63.9%

 

 

Market Data

Quote Symbol:

HOVID

Exchange:

Bursa Malaysia

Currency:

MYR

Stock Price:

0.2

Stock Price Date:

10-28-2011

52 Week Price Change %:

13.5

Market Value (mil):

160,036.8

 

SEDOL:

B1LYZG8

ISIN:

MYL7213OO001

 

Equity and Dept Distribution:

01/2007, 5-for-1 stock split.

 

 

 

Subsidiaries

Company

Percentage Owned

Country

Hovid Pharmacy Sdn Bhd

100%

MALAYSIA

Agrovid SA

100%

COLOMBIA

Hovid Limited

60%

HONG KONG SAR

Hovid Nutriworld Sdn Bhd

100%

MALAYSIA

Biodeal Pharmaceuticals Private Limited

51%

INDIA

Hovid Inc

100%

MALAYSIA

Ho Han Yor (S) Pte Ltd

80%

SINGAPORE

Javid Sdn Bhd

100%

MALAYSIA

Hovid Marketing Sdn Bhd

100%

MALAYSIA

 

 

 

 

 

Shareholders

 

 

Major Shareholders

David Ho Sue San (49.57%)

 

 

 

 

 

Key Corporate Relationships

Auditor:

KPMG LLP

Bank:

Malayan Banking Berhad, Hong Leong Bank Berhad, United Overseas Bank (Malaysia) Bhd, Affi n Investment Bank Berhad, EON Bank Berhad, Public Bank Berhad, OCBC Bank (Malaysia) Berhad

 

Auditor:

KPMG, KPMG LLP, Kpmg

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Executives Report

 

 

Board of Directors

 

Name

Title

Function

Sue San Ho

 

Executive Chairman of the Board, Managing Director

Chairman

 

Mr. Ho (David) Sue San serves as Executive Chairman of the Board and Managing Director of Hovid Bhd on January 31, 2008. He was appointed to the Board, being the first Director since incorporation of the Company on May 20, 1980. He obtained a Bachelor of Pharmacy degree from the University of Otago in 1974. He later obtained a Master of Pharmacy degree from the University of Otago in 1976. He was registered as a pharmacist with the Pharmaceutical Society of New Zealand in 1974 and as a pharmaceutical chemist by the Pharmaceutical Society of Great Britain in 1977. He was registered as a pharmacist with the Malaysian Pharmacist Board in 1980. He has also completed the Applied International Management Programme organized by the Swedish Institute of Management in 1990 and the International Top Management Seminar in the field of Quality Leadership organized by ISO Swedish Management Group in 1996. From 1978 to 1979, he was a research pharmacist with Wyeth Laboratories Ltd. Thereafter, he formed and incorporated Hovid Berhad in 1980. He was on the Board of Malaysian Biotechnology Corporation Sdn. Bhd., a subsidiary of MOF Inc in Malaysia from 2006 to 2009. He also sits on the Board of Carotech Berhad as Chairman & Managing Director.


Education

M , University of Otago
B , University of Otago

Shamsul Kamal Bin Shahruzzaman

 

Independent Non-Executive Director

Director/Board Member

 

 

Reuters Biography (Hovid Berhad)

YM Raja Shamsul Kamal Bin Shahruzzaman serves as Independent Non-Executive Director of Hovid Bhd on August 13, 2007. He was appointed to the Board of the Company on December 22, 2004 as the Non-Executive Director. He obtained a Bachelor of Science degree with Honours in Civil Engineering from the University of Newcastle upon Tyne (now Newcastle University), England. He joined Shah Alam Properties Sdn. Bhd. as a project engineer in 1984 to 1987. He left in 1987 to join Bank of Commerce Bhd. before leaving as Vice President & Group Head of Corporate Banking Department in 1991 to join Bumiputra-Commerce Holdings Berhad. Since joining Bumiputra-Commerce Holdings Berhad, he has been in numerous positions including the General Manager & Chief Executive Officer of Commerce Asset Leasing Sdn. Bhd. (1991 to 1996), General Manager of Commerce Asset Fund Managers Sdn. Bhd. (1996 to 1997) and Executive Director and Chief Executive Officer of Commerce Asset Ventures Sdn. Bhd. before leaving in July 2007. He is currently the Senior Partner at the private equity management firm of Vida Partners Sdn. Bhd. based in Kuala Lumpur. He also sits on the Board of Carotech Berhad as the Independent Non-Executive Director. He is the Chairman of the Nomination and Remuneration Committee and a member of the Audit Committee of the Company.


Education

BS Civil Engineering, Newcastle University

Chaw Teo Chuah

 

Independent Non-Executive Director

Director/Board Member

 

 

 

Dr. Chuah Chaw Teo serves as Independent Non-Executive Director of Hovid Bhd on December 22, 2004. He is a chemist by profession. He obtained a Bachelor of Science degree with Honours in 1975 from the University of Otago, where he was also given the University of Otago Science Award for ranking first in the class. Thereafter, he obtained a Doctorate degree in Applied Organic Chemistry in 1979, also from the University of Otago. He has a Diploma in Management from the Malaysian Institute of Management, which he obtained with Merit in 1987. After he obtained his Doctorate degree in 1979, Dr. Chuah worked as a post-doctoral research associate with the College of Environmental Science and Forestry of the State University of New York, a position which he held for the next two (2) years. From 1982 to 1983, he served as a lecturer in the University of Malaya, Malaysia. After he left the University of Malaya, he was attached to Yee Lee Edible Oils Sdn. Bhd. as General Manager for Research and Development. He held this position for ten (10) years, from 1983 to 1993. Presently, he is an Executive Director of Spritzer Berhad, a position that he has held since 1994. He is also an Independent Non-Executive Director of Carotech Berhad since 1991. He is a member of the Nomination and Remuneration Committee as well as the Audit Committee of the Company.


Education

DS , University of Otago
BS , University of Otago

Kwok Yee Leong

 

Independent Non-Executive Director

Director/Board Member

 

 

 

Mr. Leong Kwok Yee serves as Independent Non-Executive Director of Hovid Bhd on December 22, 2004. He is an accountant by profession. He obtained a Bachelor of Commerce degree in 1974 from the University of Otago and a Master in Business Administration from University of Macquarie (also Macquarie University) in 1989. He is a Fellow Member of both the New Zealand Institute of Chartered Accountants and Australian Institute of Chartered Accountants, having trained at Ernst & Young in Wellington, New Zealand and Sydney, Australia. He left Ernst & Young in 1981 to join Encyclopaedia Britannica (Sydney) as their Financial Controller before joining Hunter Douglas Ltd. (Sydney) in 1988 as their Treasurer/Management Accountant. He subsequently joined Dodwell, Inchcape Buying Services (Hong Kong) as their Financial Controller in 1990 and became the Finance Director in 1993. He left in 1995 to be the Chief Financial Officer of Li & Fung, Ltd. (Hong Kong) and retired on September 1, 2004. From May 1, 2006 to August 31, 2007, he was appointed as Head of Middle Office of Li & Fung (Trading) Ltd., Hong Kong. He was the Chief Financial Officer and on the Board of LiFung Trinity Ltd. (Hong Kong) from September 1, 2007 to January 31, 2009 and to August 16, 2009 respectively. He was appointed as an advisor of Li & Fung (Trading) Ltd. from February 2009 to June 30, 2010. Since July 1, 2010, he is working as a Consultant of Li & Fung (1937) Ltd. He is also an Independent Non-Executive Director of Carotech Berhad. He is the Chairman of Audit Committee and a member of the Nomination and Remuneration Committee of the Company.


Education

M Business Administration, Macquarie University
B , University of Otago

Kam Hon Liong

 

Executive Director

Director/Board Member

 

 

 

Mr. Liong Kam Hon serves as Executive Director of Hovid Bhd on February 11, 1999. He joined Hovid Pharmacy Sdn. Bhd. as a Manager on June 16, 1981. Prior to that, he served as a manager with Public Medical Supplies from 1978 to 1980. Between 1967 and 1977, he was the chief dispenser with Georgetown Dispensary Ltd.

 

Executives

 

Name

Title

Function

Sue San Ho

 

Executive Chairman of the Board, Managing Director

Managing Director

 

Mr. Ho (David) Sue San serves as Executive Chairman of the Board and Managing Director of Hovid Bhd on January 31, 2008. He was appointed to the Board, being the first Director since incorporation of the Company on May 20, 1980. He obtained a Bachelor of Pharmacy degree from the University of Otago in 1974. He later obtained a Master of Pharmacy degree from the University of Otago in 1976. He was registered as a pharmacist with the Pharmaceutical Society of New Zealand in 1974 and as a pharmaceutical chemist by the Pharmaceutical Society of Great Britain in 1977. He was registered as a pharmacist with the Malaysian Pharmacist Board in 1980. He has also completed the Applied International Management Programme organized by the Swedish Institute of Management in 1990 and the International Top Management Seminar in the field of Quality Leadership organized by ISO Swedish Management Group in 1996. From 1978 to 1979, he was a research pharmacist with Wyeth Laboratories Ltd. Thereafter, he formed and incorporated Hovid Berhad in 1980. He was on the Board of Malaysian Biotechnology Corporation Sdn. Bhd., a subsidiary of MOF Inc in Malaysia from 2006 to 2009. He also sits on the Board of Carotech Berhad as Chairman & Managing Director.


Education

M , University of Otago
B , University of Otago

David Ho

 

Managing Director

Managing Director

 

 

Tian Hock Goh

 

Company Secretary

Company Secretary

 

 

Yuet Seam Ng

 

Company Secretary

Company Secretary

 

 

Eng Brittany

 

Training Manager

Human Resources Executive

 

 

Felicia Chea

 

Human Resources Manager

Human Resources Executive

 

 

Charles Lee

 

International Marketing & Distribution Director

International Executive

 

 

Alvin Lee

 

Business Development Manager

Business Development Executive

 

 

Ming Chiu Yew

 

Regulatory Affairs Manager

Legal Executive

 

 

Ong Bee Lan

 

Production Manager

Manufacturing Executive

 

 

Ah Ling Leong

 

Purchasing Manager

Purchasing Executive

 

 

 

 

Significant Developments

 

 

 

 

Hovid Berhad Announces Striking Off Of Ho Yan Hor (S) Pte. Ltd.

Oct 20, 2011


Hovid Berhad announced that on September 28, 2011, an application was made to the Accounting and Corporate Regulatory Authority of Singapore to strike-off its 80%-owned subsidiary, Ho Yan Hor (S) Pte. Ltd. (HYH) pursuant to Section 344 of the Singapore Companies Act, Cap 50. HYH is a dormant company and has no intention to commence any business activities in future.

Hovid Berhad Announces Proposed Dividend-In-Specie

Aug 15, 2011


Hovid Berhad announced its proposed distribution of a portion of its shareholding interest in Carotech Berhad by way of dividend-in-specie to the shareholders of the Company on the basis of 25 ordinary shares of MYR 0.10 each in Carotech Berhad for every 100 ordinary shares of MYR 0.10 each held in the Company. The distribution date and entitlement date of the dividend will be announced in due course.

Hovid Berhad Announces Ownership Interest Of Ho Sue San @ David Ho Sue San

Mar 18, 2011


Hovid Berhad announced that Ho Sue San @ David Ho Sue San has an interest of 337,189,880 units, representing 44.25% of the total shares in the Company. Previously, Ho Sue San @ David Ho Sue San had 49.57% interest in the Company.

Hovid Berhad Announces Manufacture And Supply Agreement

Jan 12, 2011


Hovid Berhad announced that the Company had on November 2, 2010, entered into a Manufacturing And Supply Agreement (Supply Agreement) with Winthrop Pharmaceutical (Malaysia) Sdn Bhd (Winthrop) for the supply of pharmaceutical products, namely, Tramadol Winthrop SR 100mg, Metformin Winthrop MR 850mg and any new products as may be added from time to time for a period of three years from January 1, 2011 to December 31, 2013 with the option to extend for a further period of three years. Under the terms of the Supply Agreement, Hovid will supply annually to Winthrop a minimum quantity of 3.9 million and 664,000 tablets of Metformin Winthrop MR 850 mg and Tramadol Winthrop SR 100mg respectively. The Supply Agreement is valued at approximately MYR5.0 million for the initial three years. Winthrop (company registration number 160227-V), a company registered under law of Malaysia, having its office at Damasara Heights, Kuala Lumpur, is a pharmaceutical company engaged in the distribution of pharmaceutical products. Winthrop is a subsidiary of Sanofi-Aventis, a global diversified healthcare company with shares being traded in Paris and New York Stock Exchange.

 

 

 

 

Australia: Hovid Berhad Receives Patent for 'An effective pharmaceutical carrier for poorly bioavailable drugs'

Australian Government: 24 August 2011
[What follows is the full text of the news story.]

 

Australia, Aug. 24 -- Hovid Berhad, Malaysia, has filed an application (2007265836) on June 15, 2007, for 'An effective pharmaceutical carrier for poorly bioavailable drugs.'

The patent is effective from effective June 15, 2007, till June 15, 2027.

Inventor(s): Bee Hong Ng, David Sue San Ho, Wai Peng Choy, June Lay Choo Khoo, Kah Hay Yuen and Jia Woei Wong

Application Status: Accepted

Acceptance Date: July 26

Paid to Date: June 15, 2012

The original document can be viewed at: http://pericles.ipaustralia.gov.au/ols/auspat/applicationDetails.do?applicationNo=2007265836

For any query with respect to this article or any other content requirement, please contact Editor at htsyndication@hindustantimes.com



Hovid investors to get Carotech shares

Business Times (Malaysia): 16 August 2011
[What follows is the full text of the news story.]

 

HOVID Bhd is proposing to distribute a portion of its shareholding interest in Carotech Bhd by way of dividend-in-specie to the shareholders of Hovid, on the basis of 25 ordinary shares each in Carotech for every 100 ordinary shares each held in Hovid.

( END )



Key investments

The Straits Times: 12 January 2011
[What follows is the full text of the news story.]

 

ExxonMobil and Petronas to invest RM10 billion (S$4.2 billion) to rejuvenate mature oil fields and develop a gas project off peninsular Malaysia.

Shell Malaysia to invest RM5.1 billion in multiple projects to upgrade and build facilities across Malaysia.

Dialog Group to invest RM5 billion to build a deepwater petroleum terminal project in Pengerang, Johor. This will have a storage capacity of 5 million cubic m.

A Nuclear Power Corporation will be set up to plan for a nuclear power plant in 11 to 12 years.

Mass Rapid Transit system for Kuala Lumpur, which will cost RM36.6 billion.

Universiti Malaya to set up a Health Metropolis in Petaling Jaya, Selangor, to integrate health care, bio-research and postgraduate education.

Malaysian pharmaceutical company Hovid and join Winthrop Pharmaceuticals, a subsidiary of global firm Sanofi-Aventis, to jointly manufacture generic drugs for diabetes and pain management.

Teluk Datai Resorts to invest RM1 billion to build new hotels in Langkawi.

YTL Group, famed for its luxury resorts, to invest RM75 million to build the Pulau Gaya Resort in Sabah.

CAROLYN HONG

 

 

Annual Income Statement

 

Financials in: USD (mil)

 

Except for share items (millions) and per share items (actual units)

 

 

 

 

 

  Financial Glossary

 

 

 

30-Jun-2011

30-Jun-2010

30-Jun-2009

30-Jun-2008

30-Jun-2007

Period Length

12 Months

12 Months

12 Months

12 Months

12 Months

UpdateType/Date

Updated Normal
30-Jun-2011

Updated Normal
30-Jun-2010

Updated Normal
30-Jun-2009

Updated Normal
30-Jun-2008

Updated Normal
30-Jun-2007

Filed Currency

MYR

MYR

MYR

MYR

MYR

Exchange Rate (Period Average)

3.084602

3.385057

3.515259

3.315347

3.556314

Auditor

 

KPMG LLP

KPMG LLP

KPMG LLP

KPMG LLP

Auditor Opinion

 

No Opinion

Unqualified

Unqualified

Unqualified

 

 

 

 

 

 

    Net Sales

49.7

107.9

70.7

64.8

52.5

Revenue

49.7

107.9

70.7

64.8

52.5

Total Revenue

49.7

107.9

70.7

64.8

52.5

 

 

 

 

 

 

    Cost of Revenue

-

64.1

30.4

32.1

20.4

Cost of Revenue, Total

-

64.1

30.4

32.1

20.4

Gross Profit

49.7

43.8

40.3

32.7

32.1

 

 

 

 

 

 

    Selling/General/Administrative Expense

-

40.1

10.4

8.2

6.7

    Labor & Related Expense

-

10.6

9.9

9.9

7.5

    Advertising Expense

-

0.9

1.3

1.3

0.8

Total Selling/General/Administrative Expenses

-

51.6

21.6

19.4

15.0

Research & Development

-

0.3

0.5

0.5

0.4

    Depreciation

2.7

6.6

7.1

3.7

2.9

    Amortization of Intangibles

-

0.2

0.2

0.2

0.1

Depreciation/Amortization

2.7

6.8

7.3

3.9

2.9

        Investment Income - Operating

-

-

0.0

0.0

-

    Interest/Investment Income - Operating

-

-

0.0

0.0

-

Interest Expense (Income) - Net Operating Total

-

-

0.0

0.0

-

    Impairment-Assets Held for Use

-

7.5

0.0

-

-

Unusual Expense (Income)

-

7.5

0.0

-

-

    Other Operating Expense

45.4

5.4

8.6

3.7

3.3

    Other, Net

-2.4

-3.9

-0.1

-2.6

-0.5

Other Operating Expenses, Total

43.1

1.5

8.5

1.1

2.7

Total Operating Expense

45.8

131.8

68.4

56.9

41.5

 

 

 

 

 

 

Operating Income

4.0

-23.9

2.4

7.8

11.1

 

 

 

 

 

 

        Interest Expense - Non-Operating

-1.7

-5.3

-5.1

-4.1

-1.3

        Interest Capitalized - Non-Operating

-

0.1

1.3

2.2

-

    Interest Expense, Net Non-Operating

-1.7

-5.2

-3.8

-1.9

-1.3

        Interest Income - Non-Operating

-

0.3

0.2

0.0

0.0

        Investment Income - Non-Operating

-3.0

-

-

-

-

    Interest/Investment Income - Non-Operating

-3.0

0.3

0.2

0.0

0.0

Interest Income (Expense) - Net Non-Operating Total

-4.7

-4.9

-3.6

-1.8

-1.2

Income Before Tax

-0.7

-28.9

-1.2

6.0

9.9

 

 

 

 

 

 

Total Income Tax

1.1

-1.5

0.7

0.5

1.7

Income After Tax

-1.9

-27.4

-1.9

5.5

8.2

 

 

 

 

 

 

    Minority Interest

0.0

11.4

2.1

-0.9

-2.2

Net Income Before Extraord Items

-1.8

-15.9

0.1

4.6

6.0

Net Income

-1.8

-15.9

0.1

4.6

6.0

 

 

 

 

 

 

Income Available to Common Excl Extraord Items

-1.8

-15.9

0.1

4.6

6.0

 

 

 

 

 

 

Income Available to Common Incl Extraord Items

-1.8

-15.9

0.1

4.6

6.0

 

 

 

 

 

 

Basic/Primary Weighted Average Shares

762.1

762.1

762.1

762.1

762.1

Basic EPS Excl Extraord Items

0.00

-0.02

0.00

0.01

0.01

Basic/Primary EPS Incl Extraord Items

0.00

-0.02

0.00

0.01

0.01

Dilution Adjustment

0.0

0.0

0.0

0.0

-

Diluted Net Income

-1.8

-15.9

0.1

4.6

6.0

Diluted Weighted Average Shares

762.1

762.1

1,143.1

1,143.1

1,143.1

Diluted EPS Excl Extraord Items

0.00

-0.02

0.00

0.00

0.01

Diluted EPS Incl Extraord Items

0.00

-0.02

0.00

0.00

0.01

Dividends per Share - Common Stock Primary Issue

0.00

0.00

0.00

0.00

0.00

Gross Dividends - Common Stock

0.0

0.0

0.0

2.5

1.4

Interest Expense, Supplemental

1.7

5.0

2.5

1.9

1.3

Interest Capitalized, Supplemental

-

-0.1

-1.3

-2.2

-0.5

Depreciation, Supplemental

2.7

6.7

7.3

3.7

2.9

Total Special Items

-

9.0

0.8

0.0

-

Normalized Income Before Tax

-0.7

-19.8

-0.4

6.0

9.9

 

 

 

 

 

 

Effect of Special Items on Income Taxes

-

3.2

0.3

0.0

-

Inc Tax Ex Impact of Sp Items

1.1

1.7

1.0

0.5

1.7

Normalized Income After Tax

-1.9

-21.5

-1.4

5.5

8.2

 

 

 

 

 

 

Normalized Inc. Avail to Com.

-1.8

-10.1

0.6

4.6

6.0

 

 

 

 

 

 

Basic Normalized EPS

0.00

-0.01

0.00

0.01

0.01

Diluted Normalized EPS

0.00

-0.01

0.00

0.00

0.01

Amort of Intangibles, Supplemental

-

0.2

0.2

0.2

0.1

Rental Expenses

-

0.2

0.2

0.2

0.2

Advertising Expense, Supplemental

-

0.9

1.3

1.3

0.8

Research & Development Exp, Supplemental

-

0.3

0.5

0.5

0.4

Normalized EBIT

4.0

-14.9

3.1

7.8

11.1

Normalized EBITDA

6.7

-8.0

10.6

11.7

14.0

    Current Tax - Domestic

-

1.1

0.7

1.0

0.5

    Current Tax - Foreign

-

0.1

0.1

0.1

0.0

    Current Tax - Other

-

-

-

-0.1

-0.1

Current Tax - Total

-

1.2

0.8

1.0

0.4

    Deferred Tax - Total

-

-2.7

-0.1

-0.5

1.3

Deferred Tax - Total

-

-2.7

-0.1

-0.5

1.3

Income Tax - Total

-

-1.5

0.7

0.5

1.7

Interest Cost - Domestic

-

0.1

0.1

0.0

0.0

Service Cost - Domestic

-

0.0

0.0

0.0

0.0

Domestic Pension Plan Expense

-

0.1

0.1

0.1

0.1

Defined Contribution Expense - Domestic

-

0.6

0.6

0.8

0.7

Total Pension Expense

-

0.7

0.6

0.9

0.7

Discount Rate - Domestic

-

6.00%

6.00%

6.00%

-

Compensation Rate - Domestic

-

6.00%

6.00%

6.00%

-

Total Plan Interest Cost

-

0.1

0.1

0.0

0.0

Total Plan Service Cost

-

0.0

0.0

0.0

0.0

 

 

 

Annual Balance Sheet

Financials in: USD (mil)

 

  Financial Glossary

 

 

 

30-Jun-2011

30-Jun-2010

30-Jun-2009

30-Jun-2008

30-Jun-2007

UpdateType/Date

Updated Normal
30-Jun-2011

Reclassified Normal
30-Jun-2011

Updated Normal
30-Jun-2009

Updated Normal
30-Jun-2008

Updated Normal
30-Jun-2007

Filed Currency

MYR

MYR

MYR

MYR

MYR

Exchange Rate

3.0195

3.2375

3.515

3.2675

3.4525

Auditor

 

KPMG LLP

KPMG LLP

KPMG LLP

KPMG LLP

Auditor Opinion

 

No Opinion

Unqualified

Unqualified

Unqualified

 

 

 

 

 

 

    Cash & Equivalents

2.9

3.0

4.0

4.2

7.0

    Short Term Investments

-

-

0.0

-

-

Cash and Short Term Investments

2.9

3.0

4.0

4.2

7.0

        Accounts Receivable - Trade, Gross

-

-

12.1

21.1

6.9

        Provision for Doubtful Accounts

-

-

-0.4

-0.4

-0.4

    Trade Accounts Receivable - Net

10.4

12.5

11.7

20.7

6.5

    Other Receivables

2.1

2.3

8.1

4.9

2.2

Total Receivables, Net

12.5

14.8

19.8

25.6

8.8

    Inventories - Finished Goods

-

-

15.4

7.8

4.8

    Inventories - Work In Progress

-

-

28.5

22.3

13.8

    Inventories - Raw Materials

-

-

1.3

1.9

1.4

    Inventories - Other

-

-

1.4

1.5

2.8

Total Inventory

7.8

25.7

46.7

33.6

22.8

Total Current Assets

23.2

43.4

70.5

63.4

38.6

 

 

 

 

 

 

        Buildings

-

-

18.9

8.1

-

        Land/Improvements

-

-

4.2

4.1

12.5

        Machinery/Equipment

-

-

99.9

48.0

41.6

        Construction in Progress

-

-

5.4

64.9

26.8

    Property/Plant/Equipment - Gross

-

-

128.4

125.0

80.8

    Accumulated Depreciation

-

-

-20.4

-14.9

-10.7

Property/Plant/Equipment - Net

30.6

120.7

108.2

110.4

70.4

    Goodwill - Gross

-

-

3.6

-

-

    Accumulated Goodwill Amortization

-

-

0.0

-

-

Goodwill, Net

-

-

3.6

-

-

    Intangibles - Gross

-

-

13.2

12.2

9.5

    Accumulated Intangible Amortization

-

-

-1.8

-1.6

-1.5

Intangibles, Net

8.0

7.8

11.5

15.8

8.0

    LT Investment - Affiliate Companies

4.6

0.0

0.0

0.1

0.0

    LT Investments - Other

-

-

0.0

-

-

Long Term Investments

4.6

0.0

0.0

0.1

0.0

    Deferred Income Tax - Long Term Asset

0.0

0.0

0.0

0.0

0.1

    Other Long Term Assets

0.0

0.1

0.1

0.1

0.1

Other Long Term Assets, Total

0.0

0.1

0.1

0.1

0.2

Total Assets

66.5

172.0

193.9

189.8

117.2

 

 

 

 

 

 

Accounts Payable

4.3

7.9

7.7

11.2

2.8

Accrued Expenses

-

-

1.5

2.3

1.1

Notes Payable/Short Term Debt

11.1

43.9

46.2

43.1

20.7

Current Portion - Long Term Debt/Capital Leases

1.8

62.3

14.5

6.1

2.9

    Income Taxes Payable

0.5

0.5

0.5

0.5

0.2

    Other Payables

5.4

12.6

9.5

10.1

7.6

Other Current liabilities, Total

5.9

13.2

10.1

10.6

7.8

Total Current Liabilities

23.1

127.3

80.0

73.3

35.2

 

 

 

 

 

 

    Long Term Debt

3.0

1.5

50.6

51.5

24.8

    Capital Lease Obligations

0.6

0.2

2.0

3.0

2.4

Total Long Term Debt

3.5

1.7

52.6

54.5

27.2

Total Debt

16.4

107.9

113.3

103.7

50.7

 

 

 

 

 

 

    Deferred Income Tax - LT Liability

3.7

3.5

5.4

4.5

4.9

Deferred Income Tax

3.7

3.5

5.4

4.5

4.9

Minority Interest

1.7

7.5

11.1

12.5

11.5

    Pension Benefits - Underfunded

0.4

0.4

0.3

0.3

0.2

    Other Long Term Liabilities

2.1

0.0

-

-

-

Other Liabilities, Total

2.5

0.4

0.3

0.3

0.2

Total Liabilities

34.5

140.4

149.4

145.1

79.0

 

 

 

 

 

 

    Common Stock

25.2

23.5

21.7

23.3

22.1

Common Stock

25.2

23.5

21.7

23.3

22.1

Additional Paid-In Capital

0.0

0.0

0.0

0.0

0.0

Retained Earnings (Accumulated Deficit)

2.8

1.6

16.8

18.0

15.1

Unrealized Gain (Loss)

3.9

6.4

5.9

3.3

1.0

Total Equity

32.0

31.6

44.4

44.7

38.2

 

 

 

 

 

 

Total Liabilities & Shareholders’ Equity

66.5

172.0

193.9

189.8

117.2

 

 

 

 

 

 

    Shares Outstanding - Common Stock Primary Issue

762.1

762.1

762.1

762.1

762.1

Total Common Shares Outstanding

762.1

762.1

762.1

762.1

762.1

Number of Common Shareholders

-

-

8,462

7,412

7,597

Accumulated Goodwill Amortization Suppl.

-

-

0.0

-

-

Accumulated Intangible Amort, Suppl.

-

-

1.8

1.6

1.5

Total Long Term Debt, Supplemental

-

-

62.1

56.5

26.9

Long Term Debt Maturing within 1 Year

-

-

13.3

5.0

2.1

Long Term Debt Maturing in Year 2

-

-

10.5

8.4

5.3

Long Term Debt Maturing in Year 3

-

-

8.5

8.1

5.7

Long Term Debt Maturing in Year 4

-

-

8.5

8.1

5.1

Long Term Debt Maturing in Year 5

-

-

6.6

8.1

4.3

Long Term Debt Maturing in 2-3 Years

-

-

19.1

16.5

11.0

Long Term Debt Maturing in 4-5 Years

-

-

15.1

16.2

9.4

Long Term Debt Matur. in Year 6 & Beyond

-

-

14.5

18.7

4.4

Total Capital Leases, Supplemental

-

-

3.2

4.1

3.2

Capital Lease Payments Due in Year 1

-

-

1.1

1.1

0.7

Capital Lease Payments Due in Year 2

-

-

1.0

0.7

0.6

Capital Lease Payments Due in Year 3

-

-

0.6

0.7

0.6

Capital Lease Payments Due in Year 4

-

-

0.3

0.7

0.6

Capital Lease Payments Due in Year 5

-

-

0.1

0.7

0.6

Capital Lease Payments Due in 2-3 Years

-

-

1.6

1.5

1.2

Capital Lease Payments Due in 4-5 Years

-

-

0.4

1.5

1.2

Cap. Lease Pymts. Due in Year 6 & Beyond

-

-

0.0

0.0

0.0

Total Operating Leases, Supplemental

-

-

0.0

0.2

0.3

Operating Lease Payments Due in Year 1

-

-

0.0

0.1

0.1

Operating Lease Payments Due in Year 2

-

-

0.0

0.0

0.0

Operating Lease Payments Due in Year 3

-

-

0.0

0.0

0.0

Operating Lease Payments Due in Year 4

-

-

0.0

0.0

0.0

Operating Lease Payments Due in Year 5

-

-

0.0

0.0

0.0

Operating Lease Pymts. Due in 2-3 Years

-

-

0.0

0.0

0.1

Operating Lease Pymts. Due in 4-5 Years

-

-

0.0

0.0

0.1

Oper. Lse. Pymts. Due in Year 6 & Beyond

-

-

0.0

0.0

0.0

Pension Obligation - Domestic

-

-

0.3

0.3

0.2

Plan Assets - Domestic

-

-

0.1

0.1

0.1

Funded Status - Domestic

-

-

-0.3

-0.2

-0.1

Total Funded Status

-

-

-0.3

-0.2

-0.1

Discount Rate - Domestic

-

-

6.00%

-

-

Compensation Rate - Domestic

-

-

6.00%

-

-

Accrued Liabilities - Domestic

-

-

-0.3

-0.3

-

Net Assets Recognized on Balance Sheet

-

-

-0.3

-0.3

-

Total Plan Obligations

-

-

0.3

0.3

0.2

Total Plan Assets

-

-

0.1

0.1

0.1

 

 

 

Annual Cash Flows

Financials in: USD (mil)

 

  Financial Glossary

 

 

 

30-Jun-2011

30-Jun-2010

30-Jun-2009

30-Jun-2008

30-Jun-2007

Period Length

12 Months

12 Months

12 Months

12 Months

12 Months

UpdateType/Date

Updated Normal
30-Jun-2011

Updated Normal
30-Jun-2010

Updated Normal
30-Jun-2009

Reclassified Normal
30-Jun-2009

Updated Normal
30-Jun-2007

Filed Currency

MYR

MYR

MYR

MYR

MYR

Exchange Rate (Period Average)

3.084602

3.385057

3.515259

3.315347

3.556314

Auditor

 

KPMG LLP

KPMG LLP

KPMG LLP

KPMG LLP

Auditor Opinion

 

No Opinion

Unqualified

Unqualified

Unqualified

 

 

 

 

 

 

Net Income/Starting Line

-

-28.9

-1.2

6.0

9.9

    Depreciation

-

6.6

7.1

3.7

2.9

Depreciation/Depletion

-

6.6

7.1

3.7

2.9

    Amortization of Intangibles

-

0.2

0.2

0.2

0.1

Amortization

-

0.2

0.2

0.2

0.1

    Unusual Items

-

9.0

0.7

0.9

0.8

    Equity in Net Earnings (Loss)

-

0.0

0.1

0.0

-

    Other Non-Cash Items

-

31.8

7.7

-0.3

1.3

Non-Cash Items

-

40.8

8.6

0.7

2.0

    Accounts Receivable

-

5.2

4.0

-16.0

1.7

    Inventories

-

-4.7

-15.5

-9.2

-9.7

    Accounts Payable

-

-2.3

-2.0

11.1

3.0

    Other Operating Cash Flow

9.8

-6.1

-6.8

-4.7

-1.3

Changes in Working Capital

9.8

-7.8

-20.3

-18.8

-6.3

Cash from Operating Activities

9.8

10.9

-5.7

-8.3

8.5

 

 

 

 

 

 

    Purchase of Fixed Assets

-

-2.2

-5.8

-40.5

-24.9

    Purchase/Acquisition of Intangibles

-

-0.1

0.0

-0.3

-

Capital Expenditures

-

-2.3

-5.8

-40.7

-24.9

    Acquisition of Business

-

-2.9

0.0

-0.1

0.0

    Sale of Fixed Assets

-

0.0

0.0

0.2

0.0

    Purchase of Investments

-

-

0.0

-2.4

-

    Other Investing Cash Flow

10.2

-0.8

-1.0

-1.3

-1.1

Other Investing Cash Flow Items, Total

10.2

-3.8

-1.0

-3.6

-1.1

Cash from Investing Activities

10.2

-6.1

-6.8

-44.4

-25.9

 

 

 

 

 

 

    Other Financing Cash Flow

-13.4

5.5

0.0

-2.7

-1.9

Financing Cash Flow Items

-13.4

5.5

0.0

-2.7

-1.9

    Warrants Converted

-

-

0.0

2.3

0.0

Issuance (Retirement) of Stock, Net

-

-

0.0

2.3

0.0

    Short Term Debt, Net

-

-2.6

-0.5

17.2

8.2

        Long Term Debt Issued

-

5.2

15.1

31.8

16.5

        Long Term Debt Reduction

-

-14.8

-5.0

-2.9

-1.2

    Long Term Debt, Net

-

-9.7

10.1

28.9

15.3

Issuance (Retirement) of Debt, Net

-

-12.3

9.6

46.1

23.5

Cash from Financing Activities

-13.4

-6.8

9.6

45.7

21.6

 

 

 

 

 

 

Foreign Exchange Effects

0.0

0.0

0.1

0.1

0.0

Net Change in Cash

6.6

-1.9

-2.8

-6.9

4.2

 

 

 

 

 

 

Net Cash - Beginning Balance

-6.0

-3.6

-0.6

6.3

1.6

Net Cash - Ending Balance

0.6

-5.5

-3.4

-0.6

5.8

Cash Interest Paid

-

5.6

6.6

4.1

1.2

Cash Taxes Paid

-

1.2

0.7

0.7

0.1

 

 

 

Annual Income Statement

Financials in: USD (mil)

 

Except for share items (millions) and per share items (actual units)

 

 

 

 

 

 

 

 

 

30-Jun-2010

30-Jun-2009

30-Jun-2008

30-Jun-2007

30-Jun-2006

Period Length

12 Months

12 Months

12 Months

12 Months

12 Months

UpdateType/Date

Updated Normal
30-Jun-2010

Updated Normal
30-Jun-2009

Updated Normal
30-Jun-2008

Updated Normal
30-Jun-2007

Updated Normal
30-Jun-2006

Filed Currency

MYR

MYR

MYR

MYR

MYR

Exchange Rate (Period Average)

3.385057

3.515259

3.315347

3.556314

3.731642

Auditor

KPMG LLP

KPMG LLP

KPMG LLP

KPMG LLP

KPMG LLP

Auditor Opinion

No Opinion

Unqualified

Unqualified

Unqualified

Unqualified

 

 

 

 

 

 

    Manufacturing Sales

86.6

52.6

45.9

38.6

-

    Trading Sales

21.3

18.1

18.9

14.0

-

    Revenues

-

-

-

-

39.3

Total Revenue

107.9

70.7

64.8

52.5

39.3

 

 

 

 

 

 

    Advertisement and Maintenance

0.9

1.3

1.3

0.8

0.9

    Allowance for Doubtful Account

1.8

0.0

0.1

0.1

0.1

    Allowance for Slow Moving Inventories

28.9

0.0

-

-

-

    Amortization on Intangibles

0.2

0.2

0.1

0.1

0.1

    Amortization of Prepaid Lease

0.0

0.0

0.0

0.0

-

    Change in Inventories

-5.0

-16.7

-7.6

-9.4

-2.9

    Depreciation

6.6

7.1

3.7

2.9

1.8

    Impairment Loss for Plant & Equipment

3.8

0.0

-

-

-

    Impairment of Goodwill

3.7

0.0

-

-

-

    Other Expenses

5.4

8.6

3.7

3.3

1.8

    Other Income

-3.9

-0.1

-2.6

-0.5

-0.2

    Purchase of Trading Goods

1.6

1.9

2.1

0.8

1.5

    Raw Materials and Packing Materials Used

67.5

45.2

37.5

29.0

17.0

    Research Expenditure

0.3

0.5

0.5

0.4

0.2

    Sales Commission

0.4

0.6

0.3

0.3

0.1

    Staff Costs

10.6

9.9

9.9

7.5

6.4

    Transportation and Freight Charges

1.6

1.7

1.3

1.6

1.1

    Upkeep, Repair and Maintenance

1.2

1.1

1.2

1.0

1.0

    Utilities and Fuel

6.1

6.9

5.3

3.8

2.6

    Share of Results of a Jointly Cont. Ent.

-

0.0

0.0

-

-

    Exceptional Gain-Dilution of Int.-Sub.

-

-

-

-

0.0

Total Operating Expense

131.8

68.4

56.9

41.5

31.4

 

 

 

 

 

 

    Interest Income

0.3

0.2

0.0

0.0

-

    Financial Costs

-5.3

-5.1

-4.1

-1.3

-0.5

    Interest Capitalised

0.1

1.3

2.2

-

-

Net Income Before Taxes

-28.9

-1.2

6.0

9.9

7.4

 

 

 

 

 

 

Provision for Income Taxes

-1.5

0.7

0.5

1.7

1.3

Net Income After Taxes

-27.4

-1.9

5.5

8.2

6.1

 

 

 

 

 

 

    Minority Interest

11.4

2.1

-0.9

-2.2

-1.5

Net Income Before Extra. Items

-15.9

0.1

4.6

6.0

4.6

Net Income

-15.9

0.1

4.6

6.0

4.6

 

 

 

 

 

 

Income Available to Com Excl ExtraOrd

-15.9

0.1

4.6

6.0

4.6

 

 

 

 

 

 

Income Available to Com Incl ExtraOrd

-15.9

0.1

4.6

6.0

4.6

 

 

 

 

 

 

Basic Weighted Average Shares

762.1

762.1

762.1

762.1

762.1

Basic EPS Excluding ExtraOrdinary Items

-0.02

0.00

0.01

0.01

0.01

Basic EPS Including ExtraOrdinary Items

-0.02

0.00

0.01

0.01

0.01

Dilution Adjustment

0.0

0.0

0.0

-

-

Diluted Net Income

-15.9

0.1

4.6

6.0

4.6

Diluted Weighted Average Shares

762.1

1,143.1

1,143.1

1,143.1

762.1

Diluted EPS Excluding ExtraOrd Items

-0.02

-

0.00

0.01

0.01

Diluted EPS Including ExtraOrd Items

-0.02

-

0.00

0.01

0.01

DPS-Common Stock

0.00

0.00

0.00

0.00

0.00

Gross Dividends - Common Stock

0.0

0.0

2.5

1.4

0.0

Normalized Income Before Taxes

-19.8

-0.4

6.0

9.9

7.4

 

 

 

 

 

 

Inc Tax Ex Impact of Sp Items

1.7

1.0

0.5

1.7

1.3

Normalized Income After Taxes

-21.5

-1.4

5.5

8.2

6.1

 

 

 

 

 

 

Normalized Inc. Avail to Com.

-10.1

0.6

4.6

6.0

4.6

 

 

 

 

 

 

Basic Normalized EPS

-0.01

0.00

0.01

0.01

0.01

Diluted Normalized EPS

-0.01

0.00

0.00

0.01

0.01

Interest Expenses

5.0

2.5

1.9

1.3

0.5

Interest Capitalized

-0.1

-1.3

-2.2

-0.5

-

Depreciation

6.7

7.3

3.7

2.9

1.8

Amortization on Intangibles

0.2

0.2

0.2

0.1

0.1

Advertising Costs

0.9

1.3

1.3

0.8

1.1

Research and Development

0.3

0.5

0.5

0.4

0.2

Rental Expenses

0.2

0.2

0.2

0.2

0.1

    Current Tax - Domestic

1.1

0.7

1.0

0.5

-

    Current Tax -Foreign

0.1

0.1

0.1

0.0

-

    OverProvision for Prior Years

-

-

-0.1

-0.1

-

Current Tax - Total

1.2

0.8

1.0

0.4

-

    Deferred Tax

-2.7

-0.1

-0.5

1.3

-

Deferred Tax - Total

-2.7

-0.1

-0.5

1.3

-

Income Tax - Total

-1.5

0.7

0.5

1.7

-

Interest Cost - Manager

0.1

0.1

0.0

0.0

-

Service Cost - Manager

0.0

0.0

0.0

0.0

-

Domestic Pension Plan Expense

0.1

0.1

0.1

0.1

-

Contribution to Provident Fund

0.6

0.6

0.8

0.7

-

Total Pension Expense

0.7

0.6

0.9

0.7

-

Discount Interest - Manager

6.00%

6.00%

6.00%

-

-

Salary Escalation - Manager

6.00%

6.00%

6.00%

-

-

 

 

 

Annual Balance Sheet

Financials in: USD (mil)

 

 

 

 

 

30-Jun-2010

30-Jun-2009

30-Jun-2008

30-Jun-2007

30-Jun-2006

UpdateType/Date

Updated Normal
30-Jun-2010

Updated Normal
30-Jun-2009

Updated Normal
30-Jun-2008

Updated Normal
30-Jun-2007

Reclassified Normal
30-Jun-2007

Filed Currency

MYR

MYR

MYR

MYR

MYR

Exchange Rate

3.2375

3.515

3.2675

3.4525

3.6745

Auditor

KPMG LLP

KPMG LLP

KPMG LLP

KPMG LLP

KPMG LLP

Auditor Opinion

No Opinion

Unqualified

Unqualified

Unqualified

Unqualified

 

 

 

 

 

 

    Raw Materials

1.6

1.3

1.9

1.4

1.0

    Work-in-progress

13.6

28.5

22.3

13.8

6.1

    Finished Goods

9.0

15.4

7.8

4.8

1.8

    Trading Goods

0.9

1.0

1.1

2.4

2.7

    Packing Materials

0.6

0.5

0.5

0.5

0.5

    Trade Receivables

12.6

12.1

21.1

6.9

-

    Allowances for Doubtful Debts

-0.2

-0.4

-0.4

-0.4

-

    Trade Receivables

-

-

-

-

9.0

    Other Receivables and Prepaid Expenses

2.3

8.1

4.9

2.2

1.1

    Amount Owing by Jointly Cont. Entity

-

0.0

0.0

0.0

-

    Tax Recoverable

-

-

0.0

0.1

0.2

    Deposits With Licensed Banks

0.1

0.0

-

-

-

    Cash and Bank Balances

2.9

4.0

4.2

7.0

2.3

Total Current Assets

43.4

70.5

63.4

38.6

24.7

 

 

 

 

 

 

    Freehold Land

6.5

4.2

4.1

12.5

10.6

    Buildings

21.5

18.9

8.1

-

-

    Plant and Machinery

103.8

90.6

38.4

34.3

17.4

    Motor Vehicles

1.8

1.6

1.6

1.5

1.3

    Furniture, Fittings and Office Equipment

9.0

7.7

7.9

5.8

4.6

    Capital Work-in-progress

6.5

5.4

64.9

26.8

16.4

    Depreciation

-29.9

-20.4

-14.9

-10.7

-7.3

    Accumulated Impairment

-4.0

0.0

-

-

-

    Prepaid Lease Payments

-

-

5.2

0.0

-

    Prepaid Lease Payments

5.5

4.9

-

-

-

    Accumulated Amortisation

-0.2

-0.1

-

-

-

    Investments

-

0.0

-

-

-

    Goodwill

5.2

3.6

-

-

-

    Accumulated Impairment

-3.9

0.0

-

-

-

    Intangibles

-

-

12.2

9.5

8.5

    Product Development Expenditure

8.2

8.1

-

-

-

    Acquired Trademark

0.2

0.2

-

-

-

    Amortization on Intangibles

-1.9

-1.7

-1.6

-1.5

-1.4

    Deferred Tax

0.0

0.0

0.0

0.1

0.1

    Right to Reimbursement-Insurance Policy

0.1

0.1

0.1

0.1

0.1

    Investment in Jointly Controlled Entity

-

0.0

0.1

0.0

-

    Investment Properties

0.3

0.2

0.2

0.2

0.2

Total Assets

172.0

193.9

189.8

117.2

75.2

 

 

 

 

 

 

    Trade Payables

7.9

7.7

11.2

2.8

3.3

    Other Payables

10.9

9.5

10.1

7.6

-

    Accrued Expenses

1.7

1.5

2.3

1.1

-

    Other Payables and Accrued Expenses

-

-

-

-

4.7

    Hire Purchase Creditors

2.1

1.1

1.1

0.7

0.5

    Term Loans

60.2

13.3

5.0

2.1

0.6

    Bank Borrowings

35.3

35.1

38.3

19.7

10.6

    Bank Overdrafts

8.6

11.2

4.8

1.0

0.8

    Tax Liabilities

0.5

0.5

0.5

0.2

0.0

Total Current Liabilities

127.3

80.0

73.3

35.2

20.6

 

 

 

 

 

 

    Hire Purchase Creditors

0.2

2.0

3.0

2.4

1.6

    Term Loans

1.5

50.6

51.5

24.8

9.1

Total Long Term Debt

1.7

52.6

54.5

27.2

10.7

 

 

 

 

 

 

    Deferred Tax

3.5

5.4

4.5

4.9

3.3

    Retirement Benefit

0.4

0.3

0.3

0.2

0.1

    Minority Interest

7.5

11.1

12.5

11.5

9.1

Total Liabilities

140.4

149.4

145.1

79.0

43.8

 

 

 

 

 

 

    Share Capital

23.5

21.7

23.3

22.1

20.7

    Share Premium

0.0

0.0

0.0

0.0

0.0

    Revaluation and Other Reserves

6.4

5.9

3.3

1.0

2.3

    Retained Earnings

1.6

16.8

18.0

15.1

8.4

Total Equity

31.6

44.4

44.7

38.2

31.4

 

 

 

 

 

 

Total Liabilities & Shareholders' Equity

172.0

193.9

189.8

117.2

75.2

 

 

 

 

 

 

    S/O-Common Stock

762.1

762.1

762.1

762.1

762.1

Total Common Shares Outstanding

762.1

762.1

762.1

762.1

762.1

Accumulated Goodwill Amortization Suppl.

3.9

0.0

-

-

-

Amortization on Intangibles

2.1

1.8

1.6

1.5

1.4

Full-Time Employees

-

-

-

-

1,103

Shareholders

-

8,462

7,412

7,597

2,138

Long Term Debt Maturing Within 1 Year

60.2

13.3

5.0

2.1

0.6

Long Term Debt Maturing Within 2 Year

0.6

10.5

8.4

5.3

-

Long Term Debt Maturing Within 3 Year

0.4

8.5

8.1

5.7

-

Long Term Debt Maturing Within 4 Year

0.1

8.5

8.1

5.1

-

Long Term Debt Maturing Within 5 Years

0.1

6.6

8.1

4.3

7.2

Long Term Debt Maturing After 5 Years

0.3

14.5

18.7

4.4

1.9

Total Long Term Debt, Supplemental

61.7

62.1

56.5

26.9

9.7

Capital Lease Maturing Within 1st Year

2.1

1.1

1.1

0.7

0.6

Capital Lease Maturing Within 2 ndYears

0.1

1.0

-

-

-

Capital Lease Maturing Within 3 rdYrs

0.1

0.6

-

-

-

Capital Leae Maturing Within 4th Yrs

0.0

0.3

-

-

-

Capital Lease Maturing Within5 Years

0.0

0.1

3.0

2.4

1.7

Capital Lease Maturing After 5 Years

0.0

0.0

0.0

0.0

0.1

Interest Expenses

-

-

-

-

-0.3

Total Capital Leases

2.3

3.2

4.1

3.2

2.1

Operating Lease Maturing within 1 Year

0.0

0.0

0.1

0.1

0.1

Operating Lease Maturing within 2-5 Year

0.0

0.0

0.1

0.1

0.0

Total Operating Leases

0.1

0.0

0.2

0.3

0.1

Retirement Obligation - Manager

0.4

0.3

0.3

0.2

-

Retirement Assets - Manager

0.1

0.1

0.1

0.1

-

Funded Assets - Manager

-0.4

-0.3

-0.2

-0.1

-

Total Funded Status

-0.4

-0.3

-0.2

-0.1

-

Compensation Rate - Domestic

6.00%

6.00%

-

-

-

Discount Rate - Domestic

6.00%

6.00%

-

-

-

Accrued Liabilty

-0.4

-0.3

-0.3

-

-

Net Assets Recognized on Balance Sheet

-0.4

-0.3

-0.3

-

-

 

 

 

Annual Cash Flows

Financials in: USD (mil)

 

 

 

 

 

30-Jun-2010

30-Jun-2009

30-Jun-2008

30-Jun-2007

30-Jun-2006

Period Length

12 Months

12 Months

12 Months

12 Months

12 Months

UpdateType/Date

Updated Normal
30-Jun-2010

Updated Normal
30-Jun-2009

Reclassified Normal
30-Jun-2009

Updated Normal
30-Jun-2007

Updated Normal
30-Jun-2006

Filed Currency

MYR

MYR

MYR

MYR

MYR

Exchange Rate (Period Average)

3.385057

3.515259

3.315347

3.556314

3.731642

Auditor

KPMG LLP

KPMG LLP

KPMG LLP

KPMG LLP

KPMG LLP

Auditor Opinion

No Opinion

Unqualified

Unqualified

Unqualified

Unqualified

 

 

 

 

 

 

Net Income

-28.9

-1.2

6.0

9.9

7.4

    Depreciation

6.6

7.1

3.7

2.9

1.8

    Amortization on Intangibles

0.2

0.2

0.1

0.1

0.1

    Amortization of Prepaid Lease

0.0

0.0

0.0

-

-

    Allowance for Doubtful Debts

1.8

0.0

-

-

-

    Allowance for Slow Moving Inventories

28.9

0.1

-

-

-

    Products Research Expendit. Written Off

1.5

0.6

0.9

0.7

0.0

    Porperty, Plant & Equipment Written Off

0.1

0.1

0.0

0.0

0.0

    Disposal Porperty, Plant and Equipment

0.0

0.0

0.0

0.0

-0.1

    Defined Benefit Plan Expenses

0.1

0.1

0.1

0.0

0.0

    Change in the Fair Value of Investment P

0.0

0.0

0.0

0.0

-

    Interest Expenses

5.2

3.8

1.9

1.3

0.6

    Interest Income

-0.3

-0.2

0.0

0.0

0.0

    Share of Results of a Jointly Cont. Ent.

-

0.0

0.0

-

-

    Unrealised Loss on Foreign Exchange

-3.9

4.0

-2.2

-

-

    Imairment Loss for Plant & Equipment

3.8

0.0

0.0

-

-

    Investment in a Joinly Controlled Entity

0.0

0.1

0.0

-

-

    Impairment Loss for Goodwill

3.7

0.0

-

-

-

    Dilution of Interest Subsidiary

-

-

-

-

0.0

    Inventories

-4.7

-15.5

-9.2

-9.7

-2.9

    Trade Receivables and Other

5.2

4.0

-16.0

1.7

0.6

    Trade Payables and Other

-2.3

-2.0

11.1

3.0

2.7

    Interest Paid

-5.6

-6.6

-4.1

-1.2

-0.8

    Interest Received

0.8

0.5

0.0

0.0

0.2

    Tax Paid

-1.2

-0.7

-0.7

-0.1

-0.1

Cash from Operating Activities

10.9

-5.7

-8.3

8.5

9.6

 

 

 

 

 

 

    Capital Expenditures

-2.2

-5.8

-40.5

-24.9

-17.4

    Disposal Porperty, Plant and Equipment

0.0

0.0

0.2

0.0

0.1

    Products Research Expenditure

-0.8

-1.0

-1.2

-1.1

-1.0

    Advance to Former Holding Company

-

-

-

0.0

0.0

    Repayments from Holding Company

-

-

-

0.0

0.0

    Acquisition of Additional Shares in Sud

-

0.0

-2.4

-

-

    Acquisition of Prepaid Lease

-0.1

0.0

-0.3

-

-

    Investment in Jointly Controlled Entitie

-

0.0

-0.1

-

-

    Acquisition of Subsidiary

-2.9

0.0

-0.1

0.0

-2.7

    Incorporation of Subsidiaries

-

-

-

0.0

0.0

Cash from Investing Activities

-6.1

-6.8

-44.4

-25.9

-20.9

 

 

 

 

 

 

    Issue of Shares

-

-

-

-

0.0

    Public Issue of a Subsidiary

-

-

-

-

0.0

    Issue of Shares Costs

-

-

-

0.0

0.0

    Pledged Deposits

-0.1

0.0

-

-

-

    Proceeds from Issuance of Shares

5.6

0.0

-

-

-

    Payments of Warrants Issue Expenses

-

0.0

-0.2

0.0

-

    Payment of Warrants

-

0.0

2.3

0.0

-

    Dividends to Shareholders

-

0.0

-2.5

-1.9

-

    Short Term Bank Borrowings, net

-2.6

-0.5

17.2

8.2

3.7

    Proceeds of Term Loans

5.2

15.1

31.8

16.5

8.5

    Payment of Term Loans

-13.7

-4.0

-2.0

-0.5

-0.4

    Payment of Hire Purchase Creditors

-1.2

-1.1

-1.0

-0.7

-0.2

Cash from Financing Activities

-6.8

9.6

45.7

21.6

11.5

 

 

 

 

 

 

Foreign Exchange Effects

0.0

0.1

0.1

0.0

0.0

Net Change in Cash

-1.9

-2.8

-6.9

4.2

0.2

 

 

 

 

 

 

Cash-Beginning of Period

-3.6

-0.6

6.3

1.6

1.3

Cash-Ending of Period

-5.5

-3.4

-0.6

5.8

1.5

    Cash Interest Paid

5.6

6.6

4.1

1.2

0.6

    Cash Taxes Paid

1.2

0.7

0.7

0.1

0.1

 

 

 

 

Financial Health

Financials in: USD (mil)

 

Except for share items (millions) and per share items (actual units)

 

 

 

 

Key Indicators USD (mil)

 

Quarter
Ending
30-Jun-2011

Quarter
Ending
Yr Ago

Annual
Year End
30-Jun-2011

1 Year
Growth

3 Year
Growth

5 Year
Growth

Total Revenue1

11.4

-60.26%

49.7

-57.98%

-10.59%

0.92%

Operating Income1

0.1

-

4.0

-

-22.05%

-16.02%

Income Available to Common Excl Extraord Items1

-0.3

-

-1.8

-

-

-

Basic EPS Excl Extraord Items1

0.00

-

0.00

-

-

-

Cash from Operating Activities2

9.8

-18.14%

9.8

-18.14%

-

-3.38%

Free Cash Flow

10.0

-

10.0

-

-

-

Total Assets3

66.5

-

66.5

-63.94%

-31.34%

-6.20%

Total Liabilities3

34.5

-

34.5

-77.07%

-39.65%

-8.33%

Total Long Term Debt3

3.5

-

3.5

93.50%

-60.99%

-23.04%

Total Common Shares Outstanding3

762.1

-

762.1

0.00%

0.00%

0.00%

1-ExchangeRate: MYR to USD Average for Period

3.017945

 

3.084602

 

 

 

2-ExchangeRate: MYR to USD Average for Period

3.084602

 

3.084602

 

 

 

3-ExchangeRate: MYR to USD Period End Date

3.019500

 

3.019500

 

 

 

 

 

Key Ratios

 

30-Jun-2011

30-Jun-2010

30-Jun-2009

30-Jun-2008

30-Jun-2007

Profitability

Gross Margin

100.00%

40.59%

57.02%

50.47%

61.18%

Operating Margin

8.01%

-22.19%

3.33%

12.09%

21.07%

Pretax Margin

-1.47%

-26.75%

-1.71%

9.28%

18.76%

Net Profit Margin

-3.68%

-14.77%

0.17%

7.08%

11.41%

Financial Strength

Current Ratio

1.00

0.34

0.88

0.86

1.10

Long Term Debt/Equity

0.11

0.05

1.18

1.22

0.71

Total Debt/Equity

0.51

3.42

2.55

2.32

1.33

Management Effectiveness

Return on Assets

-1.51%

-14.96%

-1.05%

3.57%

8.54%

Return on Equity

-5.68%

-41.76%

0.28%

10.95%

17.25%

Efficiency

Receivables Turnover

3.59

6.22

3.24

3.77

5.49

Asset Turnover

0.41

0.59

0.38

0.42

0.55

Inventory Turnover

-

1.76

0.78

1.13

1.18

 

 

Market Valuation USD (mil)

Enterprise Value2

68.2

.

Price/Sales (TTM)

1.04

Enterprise Value/Revenue (TTM)

1.34

.

Price/Book (MRQ)

1.66

Enterprise Value/EBITDA (TTM)

9.97

.

Market Cap1

52.2

1-ExchangeRate: MYR to USD on 28-Oct-2011

3.063500

 

 

 

2-ExchangeRate: MYR to USD on 30-Jun-2011

3.019500

 

 

 

 

 

 

 

Annual Ratios

Financials in: USD (mil)

 

Except for share items (millions) and per share items (actual units)

 

 

 



 

 

30-Jun-2011

30-Jun-2010

30-Jun-2009

30-Jun-2008

30-Jun-2007

Financial Strength

Current Ratio

1.00

0.34

0.88

0.86

1.10

Quick/Acid Test Ratio

0.67

0.14

0.30

0.41

0.45

Working Capital1

0.1

-83.9

-9.5

-9.9

3.4

Long Term Debt/Equity

0.11

0.05

1.18

1.22

0.71

Total Debt/Equity

0.51

3.42

2.55

2.32

1.33

Long Term Debt/Total Capital

0.07

0.01

0.33

0.37

0.31

Total Debt/Total Capital

0.34

0.77

0.72

0.70

0.57

Payout Ratio

0.00%

0.00%

0.00%

55.00%

24.29%

Effective Tax Rate

-

-

-

8.28%

17.07%

Total Capital1

48.4

139.4

157.8

148.4

88.9

 

 

 

 

 

 

Efficiency

Asset Turnover

0.41

0.59

0.38

0.42

0.55

Inventory Turnover

-

1.76

0.78

1.13

1.18

Days In Inventory

-

207.98

467.81

323.78

309.62

Receivables Turnover

3.59

6.22

3.24

3.77

5.49

Days Receivables Outstanding

101.68

58.64

112.50

96.83

66.50

 

 

 

 

 

 

Profitability

Gross Margin

100.00%

40.59%

57.02%

50.47%

61.18%

Operating Margin

8.01%

-22.19%

3.33%

12.09%

21.07%

EBITDA Margin

13.46%

-15.76%

13.88%

18.06%

26.64%

EBIT Margin

8.01%

-22.19%

3.33%

12.09%

21.07%

Pretax Margin

-1.47%

-26.75%

-1.71%

9.28%

18.76%

Net Profit Margin

-3.68%

-14.77%

0.17%

7.08%

11.41%

R&D Expense/Revenue

-

0.28%

0.76%

0.81%

0.70%

COGS/Revenue

-

59.41%

42.98%

49.53%

38.82%

SG&A Expense/Revenue

-

47.87%

30.53%

29.97%

28.63%

 

 

 

 

 

 

Management Effectiveness

Return on Assets

-1.51%

-14.96%

-1.05%

3.57%

8.54%

Return on Equity

-5.68%

-41.76%

0.28%

10.95%

17.25%

 

 

 

 

 

 

Valuation

Free Cash Flow/Share2

0.01

0.01

-0.02

-0.07

-0.02

Operating Cash Flow/Share 2

0.01

0.02

-0.01

-0.01

0.01

1-ExchangeRate: MYR to USD Period End Date

3.0195

3.2375

3.515

3.2675

3.4525

2-ExchangeRate: MYR to USD Average for Period

3.0195

3.2375

3.515

3.2675

3.4525

 

Current Market Multiples

Market Cap/Earnings (TTM)

-28.34

Market Cap/Equity (MRQ)

1.66

Market Cap/Revenue (TTM)

1.04

Market Cap/EBIT (TTM)

13.01

Market Cap/EBITDA (TTM)

7.75

Enterprise Value/Earnings (TTM)

-36.49

Enterprise Value/Equity (MRQ)

2.13

Enterprise Value/Revenue (TTM)

1.34

Enterprise Value/EBIT (TTM)

16.75

Enterprise Value/EBITDA (TTM)

9.97

 

 

 

Annual Income Statement

Standardized

Financials in: USD (mil)

 

Except for share items (millions) and per share items (actual units)

 

 

 

 

 

  Financial Glossary

 

 

 

30-Jun-2011

30-Jun-2010

30-Jun-2009

30-Jun-2008

30-Jun-2007

Period Length

12 Months

12 Months

12 Months

12 Months

12 Months

UpdateType/Date

Updated Normal
30-Jun-2011

Updated Normal
30-Jun-2010

Updated Normal
30-Jun-2009

Updated Normal
30-Jun-2008

Updated Normal
30-Jun-2007

Filed Currency

MYR

MYR

MYR

MYR

MYR

Exchange Rate (Period Average)

3.084602

3.385057

3.515259

3.315347

3.556314

Auditor

 

KPMG LLP

KPMG LLP

KPMG LLP

KPMG LLP

Auditor Opinion

 

No Opinion

Unqualified

Unqualified

Unqualified

 

 

 

 

 

 

    Net Sales

49.7

107.9

70.7

64.8

52.5

Revenue

49.7

107.9

70.7

64.8

52.5

Total Revenue

49.7

107.9

70.7

64.8

52.5

 

 

 

 

 

 

    Cost of Revenue

-

64.1

30.4

32.1

20.4

Cost of Revenue, Total

-

64.1

30.4

32.1

20.4

Gross Profit

49.7

43.8

40.3

32.7

32.1

 

 

 

 

 

 

    Selling/General/Administrative Expense

-

40.1

10.4

8.2

6.7

    Labor & Related Expense

-

10.6

9.9

9.9

7.5

    Advertising Expense

-

0.9

1.3

1.3

0.8

Total Selling/General/Administrative Expenses

-

51.6

21.6

19.4

15.0

Research & Development

-

0.3

0.5

0.5

0.4

    Depreciation

2.7

6.6

7.1

3.7

2.9

    Amortization of Intangibles

-

0.2

0.2

0.2

0.1

Depreciation/Amortization

2.7

6.8

7.3

3.9

2.9

        Investment Income - Operating

-

-

0.0

0.0

-

    Interest/Investment Income - Operating

-

-

0.0

0.0

-

Interest Expense (Income) - Net Operating Total

-

-

0.0

0.0

-

    Impairment-Assets Held for Use

-

7.5

0.0

-

-

Unusual Expense (Income)

-

7.5

0.0

-

-

    Other Operating Expense

45.4

5.4

8.6

3.7

3.3

    Other, Net

-2.4

-3.9

-0.1

-2.6

-0.5

Other Operating Expenses, Total

43.1

1.5

8.5

1.1

2.7

Total Operating Expense

45.8

131.8

68.4

56.9

41.5

 

 

 

 

 

 

Operating Income

4.0

-23.9

2.4

7.8

11.1

 

 

 

 

 

 

        Interest Expense - Non-Operating

-1.7

-5.3

-5.1

-4.1

-1.3

        Interest Capitalized - Non-Operating

-

0.1

1.3

2.2

-

    Interest Expense, Net Non-Operating

-1.7

-5.2

-3.8

-1.9

-1.3

        Interest Income - Non-Operating

-

0.3

0.2

0.0

0.0

        Investment Income - Non-Operating

-3.0

-

-

-

-

    Interest/Investment Income - Non-Operating

-3.0

0.3

0.2

0.0

0.0

Interest Income (Expense) - Net Non-Operating Total

-4.7

-4.9

-3.6

-1.8

-1.2

Income Before Tax

-0.7

-28.9

-1.2

6.0

9.9

 

 

 

 

 

 

Total Income Tax

1.1

-1.5

0.7

0.5

1.7

Income After Tax

-1.9

-27.4

-1.9

5.5

8.2

 

 

 

 

 

 

    Minority Interest

0.0

11.4

2.1

-0.9

-2.2

Net Income Before Extraord Items

-1.8

-15.9

0.1

4.6

6.0

Net Income

-1.8

-15.9

0.1

4.6

6.0

 

 

 

 

 

 

Income Available to Common Excl Extraord Items

-1.8

-15.9

0.1

4.6

6.0

 

 

 

 

 

 

Income Available to Common Incl Extraord Items

-1.8

-15.9

0.1

4.6

6.0

 

 

 

 

 

 

Basic/Primary Weighted Average Shares

762.1

762.1

762.1

762.1

762.1

Basic EPS Excl Extraord Items

0.00

-0.02

0.00

0.01

0.01

Basic/Primary EPS Incl Extraord Items

0.00

-0.02

0.00

0.01

0.01

Dilution Adjustment

0.0

0.0

0.0

0.0

-

Diluted Net Income

-1.8

-15.9

0.1

4.6

6.0

Diluted Weighted Average Shares

762.1

762.1

1,143.1

1,143.1

1,143.1

Diluted EPS Excl Extraord Items

0.00

-0.02

0.00

0.00

0.01

Diluted EPS Incl Extraord Items

0.00

-0.02

0.00

0.00

0.01

Dividends per Share - Common Stock Primary Issue

0.00

0.00

0.00

0.00

0.00

Gross Dividends - Common Stock

0.0

0.0

0.0

2.5

1.4

Interest Expense, Supplemental

1.7

5.0

2.5

1.9

1.3

Interest Capitalized, Supplemental

-

-0.1

-1.3

-2.2

-0.5

Depreciation, Supplemental

2.7

6.7

7.3

3.7

2.9

Total Special Items

-

9.0

0.8

0.0

-

Normalized Income Before Tax

-0.7

-19.8

-0.4

6.0

9.9

 

 

 

 

 

 

Effect of Special Items on Income Taxes

-

3.2

0.3

0.0

-

Inc Tax Ex Impact of Sp Items

1.1

1.7

1.0

0.5

1.7

Normalized Income After Tax

-1.9

-21.5

-1.4

5.5

8.2

 

 

 

 

 

 

Normalized Inc. Avail to Com.

-1.8

-10.1

0.6

4.6

6.0

 

 

 

 

 

 

Basic Normalized EPS

0.00

-0.01

0.00

0.01

0.01

Diluted Normalized EPS

0.00

-0.01

0.00

0.00

0.01

Amort of Intangibles, Supplemental

-

0.2

0.2

0.2

0.1

Rental Expenses

-

0.2

0.2

0.2

0.2

Advertising Expense, Supplemental

-

0.9

1.3

1.3

0.8

Research & Development Exp, Supplemental

-

0.3

0.5

0.5

0.4

Normalized EBIT

4.0

-14.9

3.1

7.8

11.1

Normalized EBITDA

6.7

-8.0

10.6

11.7

14.0

    Current Tax - Domestic

-

1.1

0.7

1.0

0.5

    Current Tax - Foreign

-

0.1

0.1

0.1

0.0

    Current Tax - Other

-

-

-

-0.1

-0.1

Current Tax - Total

-

1.2

0.8

1.0

0.4

    Deferred Tax - Total

-

-2.7

-0.1

-0.5

1.3

Deferred Tax - Total

-

-2.7

-0.1

-0.5

1.3

Income Tax - Total

-

-1.5

0.7

0.5

1.7

Interest Cost - Domestic

-

0.1

0.1

0.0

0.0

Service Cost - Domestic

-

0.0

0.0

0.0

0.0

Domestic Pension Plan Expense

-

0.1

0.1

0.1

0.1

Defined Contribution Expense - Domestic

-

0.6

0.6

0.8

0.7

Total Pension Expense

-

0.7

0.6

0.9

0.7

Discount Rate - Domestic

-

6.00%

6.00%

6.00%

-

Compensation Rate - Domestic

-

6.00%

6.00%

6.00%

-

Total Plan Interest Cost

-

0.1

0.1

0.0

0.0

Total Plan Service Cost

-

0.0

0.0

0.0

0.0

 

 

 

Interim Income Statement

Standardized

Financials in: USD (mil)

 

Except for share items (millions) and per share items (actual units)

 

 

 

 

 

  Financial Glossary

 

 

 

30-Jun-2011

31-Mar-2011

31-Dec-2010

30-Sep-2010

30-Jun-2010

Period Length

3 Months

9 Months

3 Months

3 Months

3 Months

UpdateType/Date

Updated Normal
30-Jun-2011

Reclassified Special
30-Jun-2011

Updated Normal
31-Dec-2010

Updated Normal
30-Sep-2010

Reclassified Normal
30-Jun-2011

Filed Currency

MYR

MYR

MYR

MYR

MYR

Exchange Rate (Period Average)

3.017945

3.106731

3.113817

3.155953

3.242957

 

 

 

 

 

 

    Net Sales

11.4

38.3

12.6

13.4

26.8

Revenue

11.4

38.3

12.6

13.4

26.8

Total Revenue

11.4

38.3

12.6

13.4

26.8

 

 

 

 

 

 

Gross Profit

11.4

38.3

12.6

13.4

26.8

 

 

 

 

 

 

    Depreciation

0.4

2.3

0.5

1.4

-

Depreciation/Amortization

0.4

2.3

0.5

1.4

-

    Other Unusual Expense (Income)

-

-

-

-

0.0

Unusual Expense (Income)

-

-

-

-

0.0

    Other Operating Expense

11.1

34.3

10.0

14.5

62.5

    Other, Net

-0.1

-2.2

-0.3

-1.8

1.1

Other Operating Expenses, Total

11.0

32.1

9.7

12.6

63.5

Total Operating Expense

11.4

34.4

10.2

14.0

63.5

 

 

 

 

 

 

Operating Income

0.1

3.9

2.4

-0.6

-36.7

 

 

 

 

 

 

        Investment Income - Non-Operating

-0.6

-2.5

-1.3

0.3

0.0

    Interest/Investment Income - Non-Operating

-0.6

-2.5

-1.3

0.3

0.0

    Interest Income (Expense) - Net Non-Operating

-0.1

-1.6

-0.1

-1.1

-1.5

Interest Income (Expense) - Net Non-Operating Total

-0.7

-4.0

-1.5

-0.8

-1.5

Income Before Tax

-0.6

-0.1

0.9

-1.3

-38.1

 

 

 

 

 

 

Total Income Tax

-0.3

1.4

0.5

0.3

-3.1

Income After Tax

-0.3

-1.6

0.4

-1.6

-35.0

 

 

 

 

 

 

    Minority Interest

0.0

0.0

0.0

-0.1

13.4

Net Income Before Extraord Items

-0.3

-1.5

0.5

-1.7

-21.7

Net Income

-0.3

-1.5

0.5

-1.7

-21.7

 

 

 

 

 

 

Income Available to Common Excl Extraord Items

-0.3

-1.5

0.5

-1.7

-21.7

 

 

 

 

 

 

Income Available to Common Incl Extraord Items

-0.3

-1.5

0.5

-1.7

-21.7

 

 

 

 

 

 

Basic/Primary Weighted Average Shares

762.1

762.1

762.1

762.1

762.1

Basic EPS Excl Extraord Items

0.00

0.00

0.00

0.00

-0.03

Basic/Primary EPS Incl Extraord Items

0.00

0.00

0.00

0.00

-0.03

Dilution Adjustment

0.0

0.0

0.0

0.0

0.0

Diluted Net Income

-0.3

-1.5

0.5

-1.7

-21.7

Diluted Weighted Average Shares

762.1

762.1

1,143.1

762.1

762.1

Diluted EPS Excl Extraord Items

0.00

0.00

0.00

0.00

-0.03

Diluted EPS Incl Extraord Items

0.00

0.00

0.00

0.00

-0.03

Dividends per Share - Common Stock Primary Issue

0.00

0.00

0.00

0.00

0.00

Gross Dividends - Common Stock

0.0

0.0

0.0

0.0

0.0

Depreciation, Supplemental

0.4

2.3

0.5

1.4

-

Total Special Items

-

-

-

-

0.0

Normalized Income Before Tax

-0.6

-0.1

0.9

-1.3

-38.2

 

 

 

 

 

 

Effect of Special Items on Income Taxes

-

-

-

-

0.0

Inc Tax Ex Impact of Sp Items

-0.3

1.4

0.5

0.3

-3.1

Normalized Income After Tax

-0.3

-1.6

0.4

-1.6

-35.1

 

 

 

 

 

 

Normalized Inc. Avail to Com.

-0.3

-1.5

0.5

-1.7

-21.7

 

 

 

 

 

 

Basic Normalized EPS

0.00

0.00

0.00

0.00

-0.03

Diluted Normalized EPS

0.00

0.00

0.00

0.00

-0.03

Normalized EBIT

0.1

3.9

2.4

-0.6

-36.7

Normalized EBITDA

0.5

6.2

2.9

0.8

-36.7

    Current Tax - Total

-

-

0.6

0.3

-

Current Tax - Total

-

-

0.6

0.3

-

    Deferred Tax - Total

-

-

-0.1

0.0

-

Deferred Tax - Total

-

-

-0.1

0.0

-

    Other Tax

-

-

-

0.0

-

Income Tax - Total

-

-

0.5

0.3

-

 

 

 

Annual Balance Sheet

Standardized

Financials in: USD (mil)

 

Except for share items (millions) and per share items (actual units)

 

 

 

 

 

  Financial Glossary

 

 

 

30-Jun-2011

30-Jun-2010

30-Jun-2009

30-Jun-2008

30-Jun-2007

UpdateType/Date

Updated Normal
30-Jun-2011

Reclassified Normal
30-Jun-2011

Updated Normal
30-Jun-2009

Updated Normal
30-Jun-2008

Updated Normal
30-Jun-2007

Filed Currency

MYR

MYR

MYR

MYR

MYR

Exchange Rate

3.0195

3.2375

3.515

3.2675

3.4525

Auditor

 

KPMG LLP

KPMG LLP

KPMG LLP

KPMG LLP

Auditor Opinion

 

No Opinion

Unqualified

Unqualified

Unqualified

 

 

 

 

 

 

    Cash & Equivalents

2.9

3.0

4.0

4.2

7.0

    Short Term Investments

-

-

0.0

-

-

Cash and Short Term Investments

2.9

3.0

4.0

4.2

7.0

        Accounts Receivable - Trade, Gross

-

-

12.1

21.1

6.9

        Provision for Doubtful Accounts

-

-

-0.4

-0.4

-0.4

    Trade Accounts Receivable - Net

10.4

12.5

11.7

20.7

6.5

    Other Receivables

2.1

2.3

8.1

4.9

2.2

Total Receivables, Net

12.5

14.8

19.8

25.6

8.8

    Inventories - Finished Goods

-

-

15.4

7.8

4.8

    Inventories - Work In Progress

-

-

28.5

22.3

13.8

    Inventories - Raw Materials

-

-

1.3

1.9

1.4

    Inventories - Other

-

-

1.4

1.5

2.8

Total Inventory

7.8

25.7

46.7

33.6

22.8

Total Current Assets

23.2

43.4

70.5

63.4

38.6

 

 

 

 

 

 

        Buildings

-

-

18.9

8.1

-

        Land/Improvements

-

-

4.2

4.1

12.5

        Machinery/Equipment

-

-

99.9

48.0

41.6

        Construction in Progress

-

-

5.4

64.9

26.8

    Property/Plant/Equipment - Gross

-

-

128.4

125.0

80.8

    Accumulated Depreciation

-

-

-20.4

-14.9

-10.7

Property/Plant/Equipment - Net

30.6

120.7

108.2

110.4

70.4

    Goodwill - Gross

-

-

3.6

-

-

    Accumulated Goodwill Amortization

-

-

0.0

-

-

Goodwill, Net

-

-

3.6

-

-

    Intangibles - Gross

-

-

13.2

12.2

9.5

    Accumulated Intangible Amortization

-

-

-1.8

-1.6

-1.5

Intangibles, Net

8.0

7.8

11.5

15.8

8.0

    LT Investment - Affiliate Companies

4.6

0.0

0.0

0.1

0.0

    LT Investments - Other

-

-

0.0

-

-

Long Term Investments

4.6

0.0

0.0

0.1

0.0

    Deferred Income Tax - Long Term Asset

0.0

0.0

0.0

0.0

0.1

    Other Long Term Assets

0.0

0.1

0.1

0.1

0.1

Other Long Term Assets, Total

0.0

0.1

0.1

0.1

0.2

Total Assets

66.5

172.0

193.9

189.8

117.2

 

 

 

 

 

 

Accounts Payable

4.3

7.9

7.7

11.2

2.8

Accrued Expenses

-

-

1.5

2.3

1.1

Notes Payable/Short Term Debt

11.1

43.9

46.2

43.1

20.7

Current Portion - Long Term Debt/Capital Leases

1.8

62.3

14.5

6.1

2.9

    Income Taxes Payable

0.5

0.5

0.5

0.5

0.2

    Other Payables

5.4

12.6

9.5

10.1

7.6

Other Current liabilities, Total

5.9

13.2

10.1

10.6

7.8

Total Current Liabilities

23.1

127.3

80.0

73.3

35.2

 

 

 

 

 

 

    Long Term Debt

3.0

1.5

50.6

51.5

24.8

    Capital Lease Obligations

0.6

0.2

2.0

3.0

2.4

Total Long Term Debt

3.5

1.7

52.6

54.5

27.2

Total Debt

16.4

107.9

113.3

103.7

50.7

 

 

 

 

 

 

    Deferred Income Tax - LT Liability

3.7

3.5

5.4

4.5

4.9

Deferred Income Tax

3.7

3.5

5.4

4.5

4.9

Minority Interest

1.7

7.5

11.1

12.5

11.5

    Pension Benefits - Underfunded

0.4

0.4

0.3

0.3

0.2

    Other Long Term Liabilities

2.1

0.0

-

-

-

Other Liabilities, Total

2.5

0.4

0.3

0.3

0.2

Total Liabilities

34.5

140.4

149.4

145.1

79.0

 

 

 

 

 

 

    Common Stock

25.2

23.5

21.7

23.3

22.1

Common Stock

25.2

23.5

21.7

23.3

22.1

Additional Paid-In Capital

0.0

0.0

0.0

0.0

0.0

Retained Earnings (Accumulated Deficit)

2.8

1.6

16.8

18.0

15.1

Unrealized Gain (Loss)

3.9

6.4

5.9

3.3

1.0

Total Equity

32.0

31.6

44.4

44.7

38.2

 

 

 

 

 

 

Total Liabilities & Shareholders’ Equity

66.5

172.0

193.9

189.8

117.2

 

 

 

 

 

 

    Shares Outstanding - Common Stock Primary Issue

762.1

762.1

762.1

762.1

762.1

Total Common Shares Outstanding

762.1

762.1

762.1

762.1

762.1

Number of Common Shareholders

-

-

8,462

7,412

7,597

Accumulated Goodwill Amortization Suppl.

-

-

0.0

-

-

Accumulated Intangible Amort, Suppl.

-

-

1.8

1.6

1.5

Total Long Term Debt, Supplemental

-

-

62.1

56.5

26.9

Long Term Debt Maturing within 1 Year

-

-

13.3

5.0

2.1

Long Term Debt Maturing in Year 2

-

-

10.5

8.4

5.3

Long Term Debt Maturing in Year 3

-

-

8.5

8.1

5.7

Long Term Debt Maturing in Year 4

-

-

8.5

8.1

5.1

Long Term Debt Maturing in Year 5

-

-

6.6

8.1

4.3

Long Term Debt Maturing in 2-3 Years

-

-

19.1

16.5

11.0

Long Term Debt Maturing in 4-5 Years

-

-

15.1

16.2

9.4

Long Term Debt Matur. in Year 6 & Beyond

-

-

14.5

18.7

4.4

Total Capital Leases, Supplemental

-

-

3.2

4.1

3.2

Capital Lease Payments Due in Year 1

-

-

1.1

1.1

0.7

Capital Lease Payments Due in Year 2

-

-

1.0

0.7

0.6

Capital Lease Payments Due in Year 3

-

-

0.6

0.7

0.6

Capital Lease Payments Due in Year 4

-

-

0.3

0.7

0.6

Capital Lease Payments Due in Year 5

-

-

0.1

0.7

0.6

Capital Lease Payments Due in 2-3 Years

-

-

1.6

1.5

1.2

Capital Lease Payments Due in 4-5 Years

-

-

0.4

1.5

1.2

Cap. Lease Pymts. Due in Year 6 & Beyond

-

-

0.0

0.0

0.0

Total Operating Leases, Supplemental

-

-

0.0

0.2

0.3

Operating Lease Payments Due in Year 1

-

-

0.0

0.1

0.1

Operating Lease Payments Due in Year 2

-

-

0.0

0.0

0.0

Operating Lease Payments Due in Year 3

-

-

0.0

0.0

0.0

Operating Lease Payments Due in Year 4

-

-

0.0

0.0

0.0

Operating Lease Payments Due in Year 5

-

-

0.0

0.0

0.0

Operating Lease Pymts. Due in 2-3 Years

-

-

0.0

0.0

0.1

Operating Lease Pymts. Due in 4-5 Years

-

-

0.0

0.0

0.1

Oper. Lse. Pymts. Due in Year 6 & Beyond

-

-

0.0

0.0

0.0

Pension Obligation - Domestic

-

-

0.3

0.3

0.2

Plan Assets - Domestic

-

-

0.1

0.1

0.1

Funded Status - Domestic

-

-

-0.3

-0.2

-0.1

Total Funded Status

-

-

-0.3

-0.2

-0.1

Discount Rate - Domestic

-

-

6.00%

-

-

Compensation Rate - Domestic

-

-

6.00%

-

-

Accrued Liabilities - Domestic

-

-

-0.3

-0.3

-

Net Assets Recognized on Balance Sheet

-

-

-0.3

-0.3

-

Total Plan Obligations

-

-

0.3

0.3

0.2

Total Plan Assets

-

-

0.1

0.1

0.1

 

 

 

 

Interim Balance Sheet

Standardized

Financials in: USD (mil)

 

Except for share items (millions) and per share items (actual units)

 

 

 

 

 

  Financial Glossary

 

 

 

30-Jun-2011

31-Mar-2011

31-Dec-2010

30-Sep-2010

30-Jun-2010

UpdateType/Date

Updated Normal
30-Jun-2011

Updated Normal
31-Mar-2011

Updated Normal
31-Dec-2010

Updated Normal
30-Sep-2010

Reclassified Normal
30-Sep-2010

Filed Currency

MYR

MYR

MYR

MYR

MYR

Exchange Rate

3.0195

3.02875

3.0835

3.087

3.2375

 

 

 

 

 

 

    Cash

2.9

2.8

3.7

2.3

3.0

Cash and Short Term Investments

2.9

2.8

3.7

2.3

3.0

    Trade Accounts Receivable - Net

10.4

9.6

8.8

8.1

12.5

    Other Receivables

2.1

1.6

1.4

1.8

2.3

Total Receivables, Net

12.5

11.2

10.2

9.9

14.8

Total Inventory

7.8

8.1

7.8

6.9

25.7

Total Current Assets

23.2

22.1

21.7

19.1

43.4

 

 

 

 

 

 

Property/Plant/Equipment - Net

30.6

30.4

30.3

30.5

120.7

Intangibles, Net

8.0

8.9

8.5

8.4

7.8

    LT Investment - Affiliate Companies

4.6

5.6

7.0

8.8

0.0

Long Term Investments

4.6

5.6

7.0

8.8

0.0

    Deferred Income Tax - Long Term Asset

0.0

0.0

0.0

0.0

0.0

    Other Long Term Assets

0.0

0.1

0.1

0.1

0.1

Other Long Term Assets, Total

0.0

0.1

0.1

0.1

0.1

Total Assets

66.5

67.1

67.6

66.8

172.0

 

 

 

 

 

 

Accounts Payable

4.3

4.1

4.8

4.2

7.9

Notes Payable/Short Term Debt

11.1

11.6

11.7

12.5

43.9

Current Portion - Long Term Debt/Capital Leases

1.8

3.6

4.2

5.9

62.3

    Income Taxes Payable

0.5

1.0

0.7

0.5

0.5

    Other Payables

5.4

6.2

5.7

4.9

12.6

Other Current liabilities, Total

5.9

7.2

6.4

5.4

13.2

Total Current Liabilities

23.1

26.6

27.0

27.9

127.3

 

 

 

 

 

 

    Long Term Debt

3.0

1.8

2.0

1.4

1.5

    Capital Lease Obligations

0.6

0.7

0.8

0.1

0.2

Total Long Term Debt

3.5

2.5

2.9

1.6

1.7

Total Debt

16.4

17.7

18.7

19.9

107.9

 

 

 

 

 

 

    Deferred Income Tax - LT Liability

3.7

3.7

3.7

3.6

3.5

Deferred Income Tax

3.7

3.7

3.7

3.6

3.5

Minority Interest

1.7

1.7

1.8

1.8

7.5

    Pension Benefits - Underfunded

0.4

0.5

0.5

0.5

0.4

    Other Long Term Liabilities

2.1

-

-

-

-

Other Liabilities, Total

2.5

0.5

0.5

0.5

0.4

Total Liabilities

34.5

35.0

35.8

35.4

140.4

 

 

 

 

 

 

    Common Stock

25.2

25.2

24.7

24.7

23.5

Common Stock

25.2

25.2

24.7

24.7

23.5

Additional Paid-In Capital

0.0

0.0

0.0

0.0

0.0

Retained Earnings (Accumulated Deficit)

2.8

2.6

1.0

0.5

1.6

Unrealized Gain (Loss)

3.9

4.4

6.1

6.1

6.4

Total Equity

32.0

32.1

31.8

31.4

31.6

 

 

 

 

 

 

Total Liabilities & Shareholders’ Equity

66.5

67.1

67.6

66.8

172.0

 

 

 

 

 

 

    Shares Outstanding - Common Stock Primary Issue

762.1

762.1

762.1

762.1

762.1

Total Common Shares Outstanding

762.1

762.1

762.1

762.1

762.1

 

 

 

 

Annual Cash Flows

Standardized

Financials in: USD (mil)

 

Except for share items (millions) and per share items (actual units)

 

 

 

 

 

  Financial Glossary

 

 

 

30-Jun-2011

30-Jun-2010

30-Jun-2009

30-Jun-2008

30-Jun-2007

Period Length

12 Months

12 Months

12 Months

12 Months

12 Months

UpdateType/Date

Updated Normal
30-Jun-2011

Updated Normal
30-Jun-2010

Updated Normal
30-Jun-2009

Reclassified Normal
30-Jun-2009

Updated Normal
30-Jun-2007

Filed Currency

MYR

MYR

MYR

MYR

MYR

Exchange Rate (Period Average)

3.084602

3.385057

3.515259

3.315347

3.556314

Auditor

 

KPMG LLP

KPMG LLP

KPMG LLP

KPMG LLP

Auditor Opinion

 

No Opinion

Unqualified

Unqualified

Unqualified

 

 

 

 

 

 

Net Income/Starting Line

-

-28.9

-1.2

6.0

9.9

    Depreciation

-

6.6

7.1

3.7

2.9

Depreciation/Depletion

-

6.6

7.1

3.7

2.9

    Amortization of Intangibles

-

0.2

0.2

0.2

0.1

Amortization

-

0.2

0.2

0.2

0.1

    Unusual Items

-

9.0

0.7

0.9

0.8

    Equity in Net Earnings (Loss)

-

0.0

0.1

0.0

-

    Other Non-Cash Items

-

31.8

7.7

-0.3

1.3

Non-Cash Items

-

40.8

8.6

0.7

2.0

    Accounts Receivable

-

5.2

4.0

-16.0

1.7

    Inventories

-

-4.7

-15.5

-9.2

-9.7

    Accounts Payable

-

-2.3

-2.0

11.1

3.0

    Other Operating Cash Flow

9.8

-6.1

-6.8

-4.7

-1.3

Changes in Working Capital

9.8

-7.8

-20.3

-18.8

-6.3

Cash from Operating Activities

9.8

10.9

-5.7

-8.3

8.5

 

 

 

 

 

 

    Purchase of Fixed Assets

-

-2.2

-5.8

-40.5

-24.9

    Purchase/Acquisition of Intangibles

-

-0.1

0.0

-0.3

-

Capital Expenditures

-

-2.3

-5.8

-40.7

-24.9

    Acquisition of Business

-

-2.9

0.0

-0.1

0.0

    Sale of Fixed Assets

-

0.0

0.0

0.2

0.0

    Purchase of Investments

-

-

0.0

-2.4

-

    Other Investing Cash Flow

10.2

-0.8

-1.0

-1.3

-1.1

Other Investing Cash Flow Items, Total

10.2

-3.8

-1.0

-3.6

-1.1

Cash from Investing Activities

10.2

-6.1

-6.8

-44.4

-25.9

 

 

 

 

 

 

    Other Financing Cash Flow

-13.4

5.5

0.0

-2.7

-1.9

Financing Cash Flow Items

-13.4

5.5

0.0

-2.7

-1.9

    Warrants Converted

-

-

0.0

2.3

0.0

Issuance (Retirement) of Stock, Net

-

-

0.0

2.3

0.0

    Short Term Debt, Net

-

-2.6

-0.5

17.2

8.2

        Long Term Debt Issued

-

5.2

15.1

31.8

16.5

        Long Term Debt Reduction

-

-14.8

-5.0

-2.9

-1.2

    Long Term Debt, Net

-

-9.7

10.1

28.9

15.3

Issuance (Retirement) of Debt, Net

-

-12.3

9.6

46.1

23.5

Cash from Financing Activities

-13.4

-6.8

9.6

45.7

21.6

 

 

 

 

 

 

Foreign Exchange Effects

0.0

0.0

0.1

0.1

0.0

Net Change in Cash

6.6

-1.9

-2.8

-6.9

4.2

 

 

 

 

 

 

Net Cash - Beginning Balance

-6.0

-3.6

-0.6

6.3

1.6

Net Cash - Ending Balance

0.6

-5.5

-3.4

-0.6

5.8

Cash Interest Paid

-

5.6

6.6

4.1

1.2

Cash Taxes Paid

-

1.2

0.7

0.7

0.1

 

 

 

Interim Cash Flows

Standardized

Financials in: USD (mil)

 

Except for share items (millions) and per share items (actual units)

 

 

 

 

 

  Financial Glossary

 

 

 

30-Jun-2011

31-Mar-2011

31-Dec-2010

30-Sep-2010

30-Jun-2010

Period Length

12 Months

9 Months

6 Months

3 Months

12 Months

UpdateType/Date

Updated Normal
30-Jun-2011

Updated Normal
31-Mar-2011

Updated Normal
31-Dec-2010

Updated Normal
30-Sep-2010

Updated Normal
30-Jun-2010

Filed Currency

MYR

MYR

MYR

MYR

MYR

Exchange Rate (Period Average)

3.084602

3.106731

3.135144

3.155953

3.385057

 

 

 

 

 

 

    Other Operating Cash Flow

9.8

10.3

9.1

4.6

10.9

Changes in Working Capital

9.8

10.3

9.1

4.6

10.9

Cash from Operating Activities

9.8

10.3

9.1

4.6

10.9

 

 

 

 

 

 

    Other Investing Cash Flow

10.2

8.2

8.9

10.8

-6.1

Other Investing Cash Flow Items, Total

10.2

8.2

8.9

10.8

-6.1

Cash from Investing Activities

10.2

8.2

8.9

10.8

-6.1

 

 

 

 

 

 

    Other Financing Cash Flow

-13.4

-11.9

-10.6

-9.1

-6.8

Financing Cash Flow Items

-13.4

-11.9

-10.6

-9.1

-6.8

Cash from Financing Activities

-13.4

-11.9

-10.6

-9.1

-6.8

 

 

 

 

 

 

Foreign Exchange Effects

0.0

0.0

0.0

0.0

0.0

Net Change in Cash

6.6

6.6

7.4

6.3

-1.9

 

 

 

 

 

 

Net Cash - Beginning Balance

-6.0

-5.9

-5.9

-5.7

-3.6

Net Cash - Ending Balance

0.6

0.7

1.5

0.6

-5.5

Cash Interest Paid

-

-

-

-

5.6

Cash Taxes Paid

-

-

-

-

1.2

 

 

 

 

Annual Income Statement

As Reported

Financials in: USD (mil)

 

Except for share items (millions) and per share items (actual units)

 

 

 

 

 

 

 

 

 

30-Jun-2010

30-Jun-2009

30-Jun-2008

30-Jun-2007

30-Jun-2006

Period Length

12 Months

12 Months

12 Months

12 Months

12 Months

UpdateType/Date

Updated Normal
30-Jun-2010

Updated Normal
30-Jun-2009

Updated Normal
30-Jun-2008

Updated Normal
30-Jun-2007

Updated Normal
30-Jun-2006

Filed Currency

MYR

MYR

MYR

MYR

MYR

Exchange Rate (Period Average)

3.385057

3.515259

3.315347

3.556314

3.731642

Auditor

KPMG LLP

KPMG LLP

KPMG LLP

KPMG LLP

KPMG LLP

Auditor Opinion

No Opinion

Unqualified

Unqualified

Unqualified

Unqualified

 

 

 

 

 

 

    Manufacturing Sales

86.6

52.6

45.9

38.6

-

    Trading Sales

21.3

18.1

18.9

14.0

-

    Revenues

-

-

-

-

39.3

Total Revenue

107.9

70.7

64.8

52.5

39.3

 

 

 

 

 

 

    Advertisement and Maintenance

0.9

1.3

1.3

0.8

0.9

    Allowance for Doubtful Account

1.8

0.0

0.1

0.1

0.1

    Allowance for Slow Moving Inventories

28.9

0.0

-

-

-

    Amortization on Intangibles

0.2

0.2

0.1

0.1

0.1

    Amortization of Prepaid Lease

0.0

0.0

0.0

0.0

-

    Change in Inventories

-5.0

-16.7

-7.6

-9.4

-2.9

    Depreciation

6.6

7.1

3.7

2.9

1.8

    Impairment Loss for Plant & Equipment

3.8

0.0

-

-

-

    Impairment of Goodwill

3.7

0.0

-

-

-

    Other Expenses

5.4

8.6

3.7

3.3

1.8

    Other Income

-3.9

-0.1

-2.6

-0.5

-0.2

    Purchase of Trading Goods

1.6

1.9

2.1

0.8

1.5

    Raw Materials and Packing Materials Used

67.5

45.2

37.5

29.0

17.0

    Research Expenditure

0.3

0.5

0.5

0.4

0.2

    Sales Commission

0.4

0.6

0.3

0.3

0.1

    Staff Costs

10.6

9.9

9.9

7.5

6.4

    Transportation and Freight Charges

1.6

1.7

1.3

1.6

1.1

    Upkeep, Repair and Maintenance

1.2

1.1

1.2

1.0

1.0

    Utilities and Fuel

6.1

6.9

5.3

3.8

2.6

    Share of Results of a Jointly Cont. Ent.

-

0.0

0.0

-

-

    Exceptional Gain-Dilution of Int.-Sub.

-

-

-

-

0.0

Total Operating Expense

131.8

68.4

56.9

41.5

31.4

 

 

 

 

 

 

    Interest Income

0.3

0.2

0.0

0.0

-

    Financial Costs

-5.3

-5.1

-4.1

-1.3

-0.5

    Interest Capitalised

0.1

1.3

2.2

-

-

Net Income Before Taxes

-28.9

-1.2

6.0

9.9

7.4

 

 

 

 

 

 

Provision for Income Taxes

-1.5

0.7

0.5

1.7

1.3

Net Income After Taxes

-27.4

-1.9

5.5

8.2

6.1

 

 

 

 

 

 

    Minority Interest

11.4

2.1

-0.9

-2.2

-1.5

Net Income Before Extra. Items

-15.9

0.1

4.6

6.0

4.6

Net Income

-15.9

0.1

4.6

6.0

4.6

 

 

 

 

 

 

Income Available to Com Excl ExtraOrd

-15.9

0.1

4.6

6.0

4.6

 

 

 

 

 

 

Income Available to Com Incl ExtraOrd

-15.9

0.1

4.6

6.0

4.6

 

 

 

 

 

 

Basic Weighted Average Shares

762.1

762.1

762.1

762.1

762.1

Basic EPS Excluding ExtraOrdinary Items

-0.02

0.00

0.01

0.01

0.01

Basic EPS Including ExtraOrdinary Items

-0.02

0.00

0.01

0.01

0.01

Dilution Adjustment

0.0

0.0

0.0

-

-

Diluted Net Income

-15.9

0.1

4.6

6.0

4.6

Diluted Weighted Average Shares

762.1

1,143.1

1,143.1

1,143.1

762.1

Diluted EPS Excluding ExtraOrd Items

-0.02

-

0.00

0.01

0.01

Diluted EPS Including ExtraOrd Items

-0.02

-

0.00

0.01

0.01

DPS-Common Stock

0.00

0.00

0.00

0.00

0.00

Gross Dividends - Common Stock

0.0

0.0

2.5

1.4

0.0

Normalized Income Before Taxes

-19.8

-0.4

6.0

9.9

7.4

 

 

 

 

 

 

Inc Tax Ex Impact of Sp Items

1.7

1.0

0.5

1.7

1.3

Normalized Income After Taxes

-21.5

-1.4

5.5

8.2

6.1

 

 

 

 

 

 

Normalized Inc. Avail to Com.

-10.1

0.6

4.6

6.0

4.6

 

 

 

 

 

 

Basic Normalized EPS

-0.01

0.00

0.01

0.01

0.01

Diluted Normalized EPS

-0.01

0.00

0.00

0.01

0.01

Interest Expenses

5.0

2.5

1.9

1.3

0.5

Interest Capitalized

-0.1

-1.3

-2.2

-0.5

-

Depreciation

6.7

7.3

3.7

2.9

1.8

Amortization on Intangibles

0.2

0.2

0.2

0.1

0.1

Advertising Costs

0.9

1.3

1.3

0.8

1.1

Research and Development

0.3

0.5

0.5

0.4

0.2

Rental Expenses

0.2

0.2

0.2

0.2

0.1

    Current Tax - Domestic

1.1

0.7

1.0

0.5

-

    Current Tax -Foreign

0.1

0.1

0.1

0.0

-

    OverProvision for Prior Years

-

-

-0.1

-0.1

-

Current Tax - Total

1.2

0.8

1.0

0.4

-

    Deferred Tax

-2.7

-0.1

-0.5

1.3

-

Deferred Tax - Total

-2.7

-0.1

-0.5

1.3

-

Income Tax - Total

-1.5

0.7

0.5

1.7

-

Interest Cost - Manager

0.1

0.1

0.0

0.0

-

Service Cost - Manager

0.0

0.0

0.0

0.0

-

Domestic Pension Plan Expense

0.1

0.1

0.1

0.1

-

Contribution to Provident Fund

0.6

0.6

0.8

0.7

-

Total Pension Expense

0.7

0.6

0.9

0.7

-

Discount Interest - Manager

6.00%

6.00%

6.00%

-

-

Salary Escalation - Manager

6.00%

6.00%

6.00%

-

-

 

 

 

 

Interim Income Statement

As Reported

Financials in: USD (mil)

 

Except for share items (millions) and per share items (actual units)

 

 

 

 

 

 

 

 

 

31-Mar-2011

31-Dec-2010

30-Sep-2010

30-Jun-2010

31-Mar-2010

Period Length

3 Months

3 Months

3 Months

3 Months

3 Months

UpdateType/Date

Updated Normal
31-Mar-2011

Updated Normal
31-Dec-2010

Updated Normal
30-Sep-2010

Updated Normal
30-Jun-2010

Updated Normal
31-Mar-2010

Filed Currency

MYR

MYR

MYR

MYR

MYR

Exchange Rate (Period Average)

3.048714

3.113817

3.155953

3.242957

3.372797

 

 

 

 

 

 

    Revenues

12.2

12.6

13.4

26.8

31.7

Total Revenue

12.2

12.6

13.4

26.8

31.7

 

 

 

 

 

 

    Other Operating Income

-0.1

-0.3

-1.8

1.1

-2.2

    Operating Expenses

9.7

10.0

14.5

62.4

26.0

    Depreciation

0.5

0.5

1.4

-

2.3

    Depreciation

-

-

-

0.0

-

Total Operating Expense

10.1

10.2

14.0

63.5

26.1

 

 

 

 

 

 

    Finance Costs

-0.4

-0.1

-1.1

-1.5

-1.1

    Share of profit of associate, net of tax

-1.5

-1.3

0.3

-

0.0

Net Income Before Taxes

0.2

0.9

-1.3

-38.1

4.5

 

 

 

 

 

 

Provision for Income Taxes

0.6

0.5

0.3

-3.1

0.7

Net Income After Taxes

-0.3

0.4

-1.6

-35.0

3.8

 

 

 

 

 

 

    Minority Interest

0.1

0.0

-0.1

13.4

-1.2

Net Income Before Extra. Items

-0.3

0.5

-1.7

-21.7

2.6

Net Income

-0.3

0.5

-1.7

-21.7

2.6

 

 

 

 

 

 

Income Available to Com Excl ExtraOrd

-0.3

0.5

-1.7

-21.7

2.6

 

 

 

 

 

 

Income Available to Com Incl ExtraOrd

-0.3

0.5

-1.7

-21.7

2.6

 

 

 

 

 

 

Basic Weighted Average Shares

762.1

762.1

762.1

762.1

762.1

Basic EPS Excluding ExtraOrdinary Items

0.00

0.00

0.00

-0.03

0.00

Basic EPS Including ExtraOrdinary Items

0.00

0.00

0.00

-0.03

0.00

Dilution Adjustment

0.0

0.0

0.0

0.0

0.0

Diluted Net Income

-0.3

0.5

-1.7

-21.7

2.6

Diluted Weighted Average Shares

762.1

1,143.1

762.1

762.1

1,143.1

Diluted EPS Excluding ExtraOrd Items

0.00

0.00

0.00

-0.03

0.00

Diluted EPS Including ExtraOrd Items

0.00

0.00

0.00

-0.03

0.00

DPS-Common Stock

0.00

0.00

0.00

0.00

0.00

Gross Dividends - Common Stock

0.0

0.0

0.0

0.0

0.0

Normalized Income Before Taxes

0.2

0.9

-1.3

-38.2

4.5

 

 

 

 

 

 

Inc Tax Ex Impact of Sp Items

0.6

0.5

0.3

-3.1

0.7

Normalized Income After Taxes

-0.3

0.4

-1.6

-35.1

3.8

 

 

 

 

 

 

Normalized Inc. Avail to Com.

-0.3

0.5

-1.7

-21.7

2.6

 

 

 

 

 

 

Basic Normalized EPS

0.00

0.00

0.00

-0.03

0.00

Diluted Normalized EPS

0.00

0.00

0.00

-0.03

0.00

Depreciation

0.5

0.5

1.4

-

2.3

    Income Taxation

0.4

0.6

0.3

0.5

0.2

Current Tax - Total

0.4

0.6

0.3

0.5

0.2

    Deferred Taxation

0.1

-0.1

0.0

-3.6

0.5

Deferred Tax - Total

0.1

-0.1

0.0

-3.6

0.5

    Adjustments

-

-

0.0

-

-

Income Tax - Total

0.6

0.5

0.3

-3.1

0.7

 

 

 

Annual Balance Sheet

As Reported

Financials in: USD (mil)

 

Except for share items (millions) and per share items (actual units)

 

 

 

 

 

 

 

 

 

30-Jun-2010

30-Jun-2009

30-Jun-2008

30-Jun-2007

30-Jun-2006

UpdateType/Date

Updated Normal
30-Jun-2010

Updated Normal
30-Jun-2009

Updated Normal
30-Jun-2008

Updated Normal
30-Jun-2007

Reclassified Normal
30-Jun-2007

Filed Currency

MYR

MYR

MYR

MYR

MYR

Exchange Rate

3.2375

3.515

3.2675

3.4525

3.6745

Auditor

KPMG LLP

KPMG LLP

KPMG LLP

KPMG LLP

KPMG LLP

Auditor Opinion

No Opinion

Unqualified

Unqualified

Unqualified

Unqualified

 

 

 

 

 

 

    Raw Materials

1.6

1.3

1.9

1.4

1.0

    Work-in-progress

13.6

28.5

22.3

13.8

6.1

    Finished Goods

9.0

15.4

7.8

4.8

1.8

    Trading Goods

0.9

1.0

1.1

2.4

2.7

    Packing Materials

0.6

0.5

0.5

0.5

0.5

    Trade Receivables

12.6

12.1

21.1

6.9

-

    Allowances for Doubtful Debts

-0.2

-0.4

-0.4

-0.4

-

    Trade Receivables

-

-

-

-

9.0

    Other Receivables and Prepaid Expenses

2.3

8.1

4.9

2.2

1.1

    Amount Owing by Jointly Cont. Entity

-

0.0

0.0

0.0

-

    Tax Recoverable

-

-

0.0

0.1

0.2

    Deposits With Licensed Banks

0.1

0.0

-

-

-

    Cash and Bank Balances

2.9

4.0

4.2

7.0

2.3

Total Current Assets

43.4

70.5

63.4

38.6

24.7

 

 

 

 

 

 

    Freehold Land

6.5

4.2

4.1

12.5

10.6

    Buildings

21.5

18.9

8.1

-

-

    Plant and Machinery

103.8

90.6

38.4

34.3

17.4

    Motor Vehicles

1.8

1.6

1.6

1.5

1.3

    Furniture, Fittings and Office Equipment

9.0

7.7

7.9

5.8

4.6

    Capital Work-in-progress

6.5

5.4

64.9

26.8

16.4

    Depreciation

-29.9

-20.4

-14.9

-10.7

-7.3

    Accumulated Impairment

-4.0

0.0

-

-

-

    Prepaid Lease Payments

-

-

5.2

0.0

-

    Prepaid Lease Payments

5.5

4.9

-

-

-

    Accumulated Amortisation

-0.2

-0.1

-

-

-

    Investments

-

0.0

-

-

-

    Goodwill

5.2

3.6

-

-

-

    Accumulated Impairment

-3.9

0.0

-

-

-

    Intangibles

-

-

12.2

9.5

8.5

    Product Development Expenditure

8.2

8.1

-

-

-

    Acquired Trademark

0.2

0.2

-

-

-

    Amortization on Intangibles

-1.9

-1.7

-1.6

-1.5

-1.4

    Deferred Tax

0.0

0.0

0.0

0.1

0.1

    Right to Reimbursement-Insurance Policy

0.1

0.1

0.1

0.1

0.1

    Investment in Jointly Controlled Entity

-

0.0

0.1

0.0

-

    Investment Properties

0.3

0.2

0.2

0.2

0.2

Total Assets

172.0

193.9

189.8

117.2

75.2

 

 

 

 

 

 

    Trade Payables

7.9

7.7

11.2

2.8

3.3

    Other Payables

10.9

9.5

10.1

7.6

-

    Accrued Expenses

1.7

1.5

2.3

1.1

-

    Other Payables and Accrued Expenses

-

-

-

-

4.7

    Hire Purchase Creditors

2.1

1.1

1.1

0.7

0.5

    Term Loans

60.2

13.3

5.0

2.1

0.6

    Bank Borrowings

35.3

35.1

38.3

19.7

10.6

    Bank Overdrafts

8.6

11.2

4.8

1.0

0.8

    Tax Liabilities

0.5

0.5

0.5

0.2

0.0

Total Current Liabilities

127.3

80.0

73.3

35.2

20.6

 

 

 

 

 

 

    Hire Purchase Creditors

0.2

2.0

3.0

2.4

1.6

    Term Loans

1.5

50.6

51.5

24.8

9.1

Total Long Term Debt

1.7

52.6

54.5

27.2

10.7

 

 

 

 

 

 

    Deferred Tax

3.5

5.4

4.5

4.9

3.3

    Retirement Benefit

0.4

0.3

0.3

0.2

0.1

    Minority Interest

7.5

11.1

12.5

11.5

9.1

Total Liabilities

140.4

149.4

145.1

79.0

43.8

 

 

 

 

 

 

    Share Capital

23.5

21.7

23.3

22.1

20.7

    Share Premium

0.0

0.0

0.0

0.0

0.0

    Revaluation and Other Reserves

6.4

5.9

3.3

1.0

2.3

    Retained Earnings

1.6

16.8

18.0

15.1

8.4

Total Equity

31.6

44.4

44.7

38.2

31.4

 

 

 

 

 

 

Total Liabilities & Shareholders' Equity

172.0

193.9

189.8

117.2

75.2

 

 

 

 

 

 

    S/O-Common Stock

762.1

762.1

762.1

762.1

762.1

Total Common Shares Outstanding

762.1

762.1

762.1

762.1

762.1

Accumulated Goodwill Amortization Suppl.

3.9

0.0

-

-

-

Amortization on Intangibles

2.1

1.8

1.6

1.5

1.4

Full-Time Employees

-

-

-

-

1,103

Shareholders

-

8,462

7,412

7,597

2,138

Long Term Debt Maturing Within 1 Year

60.2

13.3

5.0

2.1

0.6

Long Term Debt Maturing Within 2 Year

0.6

10.5

8.4

5.3

-

Long Term Debt Maturing Within 3 Year

0.4

8.5

8.1

5.7

-

Long Term Debt Maturing Within 4 Year

0.1

8.5

8.1

5.1

-

Long Term Debt Maturing Within 5 Years

0.1

6.6

8.1

4.3

7.2

Long Term Debt Maturing After 5 Years

0.3

14.5

18.7

4.4

1.9

Total Long Term Debt, Supplemental

61.7

62.1

56.5

26.9

9.7

Capital Lease Maturing Within 1st Year

2.1

1.1

1.1

0.7

0.6

Capital Lease Maturing Within 2 ndYears

0.1

1.0

-

-

-

Capital Lease Maturing Within 3 rdYrs

0.1

0.6

-

-

-

Capital Leae Maturing Within 4th Yrs

0.0

0.3

-

-

-

Capital Lease Maturing Within5 Years

0.0

0.1

3.0

2.4

1.7

Capital Lease Maturing After 5 Years

0.0

0.0

0.0

0.0

0.1

Interest Expenses

-

-

-

-

-0.3

Total Capital Leases

2.3

3.2

4.1

3.2

2.1

Operating Lease Maturing within 1 Year

0.0

0.0

0.1

0.1

0.1

Operating Lease Maturing within 2-5 Year

0.0

0.0

0.1

0.1

0.0

Total Operating Leases

0.1

0.0

0.2

0.3

0.1

Retirement Obligation - Manager

0.4

0.3

0.3

0.2

-

Retirement Assets - Manager

0.1

0.1

0.1

0.1

-

Funded Assets - Manager

-0.4

-0.3

-0.2

-0.1

-

Total Funded Status

-0.4

-0.3

-0.2

-0.1

-

Compensation Rate - Domestic

6.00%

6.00%

-

-

-

Discount Rate - Domestic

6.00%

6.00%

-

-

-

Accrued Liabilty

-0.4

-0.3

-0.3

-

-

Net Assets Recognized on Balance Sheet

-0.4

-0.3

-0.3

-

-

 

 

 

 

Interim Balance Sheet

As Reported

Financials in: USD (mil)

 

Except for share items (millions) and per share items (actual units)

 

 

 

 

 

 

 

 

 

31-Mar-2011

31-Dec-2010

30-Sep-2010

30-Jun-2010

31-Mar-2010

UpdateType/Date

Updated Normal
31-Mar-2011

Updated Normal
31-Dec-2010

Updated Normal
30-Sep-2010

Reclassified Normal
30-Sep-2010

Updated Normal
31-Mar-2010

Filed Currency

MYR

MYR

MYR

MYR

MYR

Exchange Rate

3.02875

3.0835

3.087

3.2375

3.262

 

 

 

 

 

 

    Inventories

8.1

7.8

6.9

25.7

56.2

    Trade Receivables

9.1

8.5

7.8

12.5

14.2

    Other Receivables and Prepaid Expenses

1.6

1.4

1.8

2.3

8.8

    Amount Owing by Jointly Cont. Enty./Asso

0.5

0.3

0.2

0.0

-

    Cash and Bank Balances

2.8

3.7

2.3

3.0

3.8

Total Current Assets

22.1

21.7

19.1

43.4

83.1

 

 

 

 

 

 

    Property, Plant and Equipment, net

30.2

30.0

30.2

120.4

110.8

    Intangibles, net

8.9

8.5

8.4

7.8

11.8

    Investment Properties

0.3

0.3

0.3

0.3

0.3

    Investment in Associate Companies

5.6

7.0

8.8

0.0

-

    Deferred Tax

0.0

0.0

0.0

0.0

0.0

    Right to Reimbursement-Insurance Policy

0.1

0.1

0.1

0.1

0.1

    Prepaid Lease Rent

-

-

-

-

5.1

Total Assets

67.1

67.6

66.8

172.0

211.2

 

 

 

 

 

 

    Trade Payables

4.1

4.8

4.2

7.9

5.1

    Other Payables and Accrued Expenses

6.2

5.7

4.9

12.6

12.8

    Term Loans

2.9

3.4

4.2

60.2

17.7

    Short Term Borrowing

9.8

9.8

10.8

35.3

39.5

    Bank Overdrafts

1.8

1.8

1.7

8.6

4.2

    Hire Purchase Creditors

0.7

0.8

1.6

2.1

1.1

    Tax Liabilities

1.0

0.7

0.5

0.5

0.7

Total Current Liabilities

26.6

27.0

27.9

127.3

81.1

 

 

 

 

 

 

    Term Loans

1.8

2.0

1.4

1.5

49.5

    Hire Purchase Creditors

0.7

0.8

0.1

0.2

1.4

Total Long Term Debt

2.5

2.9

1.6

1.7

50.9

 

 

 

 

 

 

    Deferred Tax

3.7

3.7

3.6

3.5

6.6

    Retirement Benefit

0.5

0.5

0.5

0.4

0.4

    Minority Interest

1.7

1.8

1.8

7.5

19.2

Total Liabilities

35.0

35.8

35.4

140.4

158.2

 

 

 

 

 

 

    Share Capital

25.2

24.7

24.7

23.5

23.4

    Share Premium

0.0

0.0

0.0

0.0

0.0

    Revaluation and Other Reserves

4.4

6.1

6.1

6.4

6.5

    Retained Earnings

2.6

1.0

0.5

1.6

23.2

Total Equity

32.1

31.8

31.4

31.6

53.0

 

 

 

 

 

 

Total Liabilities & Shareholders' Equity

67.1

67.6

66.8

172.0

211.2

 

 

 

 

 

 

    S/O-Common Stock

762.1

762.1

762.1

762.1

762.1

Total Common Shares Outstanding

762.1

762.1

762.1

762.1

762.1

 

 

 

 

Annual Cash Flows

As Reported

Financials in: USD (mil)

 

Except for share items (millions) and per share items (actual units)

 

 

 

 

 

 

 

 

 

30-Jun-2010

30-Jun-2009

30-Jun-2008

30-Jun-2007

30-Jun-2006

Period Length

12 Months

12 Months

12 Months

12 Months

12 Months

UpdateType/Date

Updated Normal
30-Jun-2010

Updated Normal
30-Jun-2009

Reclassified Normal
30-Jun-2009

Updated Normal
30-Jun-2007

Updated Normal
30-Jun-2006

Filed Currency

MYR

MYR

MYR

MYR

MYR

Exchange Rate (Period Average)

3.385057

3.515259

3.315347

3.556314

3.731642

Auditor

KPMG LLP

KPMG LLP

KPMG LLP

KPMG LLP

KPMG LLP

Auditor Opinion

No Opinion

Unqualified

Unqualified

Unqualified

Unqualified

 

 

 

 

 

 

Net Income

-28.9

-1.2

6.0

9.9

7.4

    Depreciation

6.6

7.1

3.7

2.9

1.8

    Amortization on Intangibles

0.2

0.2

0.1

0.1

0.1

    Amortization of Prepaid Lease

0.0

0.0

0.0

-

-

    Allowance for Doubtful Debts

1.8

0.0

-

-

-

    Allowance for Slow Moving Inventories

28.9

0.1

-

-

-

    Products Research Expendit. Written Off

1.5

0.6

0.9

0.7

0.0

    Porperty, Plant & Equipment Written Off

0.1

0.1

0.0

0.0

0.0

    Disposal Porperty, Plant and Equipment

0.0

0.0

0.0

0.0

-0.1

    Defined Benefit Plan Expenses

0.1

0.1

0.1

0.0

0.0

    Change in the Fair Value of Investment P

0.0

0.0

0.0

0.0

-

    Interest Expenses

5.2

3.8

1.9

1.3

0.6

    Interest Income

-0.3

-0.2

0.0

0.0

0.0

    Share of Results of a Jointly Cont. Ent.

-

0.0

0.0

-

-

    Unrealised Loss on Foreign Exchange

-3.9

4.0

-2.2

-

-

    Imairment Loss for Plant & Equipment

3.8

0.0

0.0

-

-

    Investment in a Joinly Controlled Entity

0.0

0.1

0.0

-

-

    Impairment Loss for Goodwill

3.7

0.0

-

-

-

    Dilution of Interest Subsidiary

-

-

-

-

0.0

    Inventories

-4.7

-15.5

-9.2

-9.7

-2.9

    Trade Receivables and Other

5.2

4.0

-16.0

1.7

0.6

    Trade Payables and Other

-2.3

-2.0

11.1

3.0

2.7

    Interest Paid

-5.6

-6.6

-4.1

-1.2

-0.8

    Interest Received

0.8

0.5

0.0

0.0

0.2

    Tax Paid

-1.2

-0.7

-0.7

-0.1

-0.1

Cash from Operating Activities

10.9

-5.7

-8.3

8.5

9.6

 

 

 

 

 

 

    Capital Expenditures

-2.2

-5.8

-40.5

-24.9

-17.4

    Disposal Porperty, Plant and Equipment

0.0

0.0

0.2

0.0

0.1

    Products Research Expenditure

-0.8

-1.0

-1.2

-1.1

-1.0

    Advance to Former Holding Company

-

-

-

0.0

0.0

    Repayments from Holding Company

-

-

-

0.0

0.0

    Acquisition of Additional Shares in Sud

-

0.0

-2.4

-

-

    Acquisition of Prepaid Lease

-0.1

0.0

-0.3

-

-

    Investment in Jointly Controlled Entitie

-

0.0

-0.1

-

-

    Acquisition of Subsidiary

-2.9

0.0

-0.1

0.0

-2.7

    Incorporation of Subsidiaries

-

-

-

0.0

0.0

Cash from Investing Activities

-6.1

-6.8

-44.4

-25.9

-20.9

 

 

 

 

 

 

    Issue of Shares

-

-

-

-

0.0

    Public Issue of a Subsidiary

-

-

-

-

0.0

    Issue of Shares Costs

-

-

-

0.0

0.0

    Pledged Deposits

-0.1

0.0

-

-

-

    Proceeds from Issuance of Shares

5.6

0.0

-

-

-

    Payments of Warrants Issue Expenses

-

0.0

-0.2

0.0

-

    Payment of Warrants

-

0.0

2.3

0.0

-

    Dividends to Shareholders

-

0.0

-2.5

-1.9

-

    Short Term Bank Borrowings, net

-2.6

-0.5

17.2

8.2

3.7

    Proceeds of Term Loans

5.2

15.1

31.8

16.5

8.5

    Payment of Term Loans

-13.7

-4.0

-2.0

-0.5

-0.4

    Payment of Hire Purchase Creditors

-1.2

-1.1

-1.0

-0.7

-0.2

Cash from Financing Activities

-6.8

9.6

45.7

21.6

11.5

 

 

 

 

 

 

Foreign Exchange Effects

0.0

0.1

0.1

0.0

0.0

Net Change in Cash

-1.9

-2.8

-6.9

4.2

0.2

 

 

 

 

 

 

Cash-Beginning of Period

-3.6

-0.6

6.3

1.6

1.3

Cash-Ending of Period

-5.5

-3.4

-0.6

5.8

1.5

    Cash Interest Paid

5.6

6.6

4.1

1.2

0.6

    Cash Taxes Paid

1.2

0.7

0.7

0.1

0.1

 

 

 

 

Interim Cash Flows

As Reported

Financials in: USD (mil)

 

Except for share items (millions) and per share items (actual units)

 

 

 

 

 

 

 

 

 

31-Mar-2011

31-Dec-2010

30-Sep-2010

30-Jun-2010

31-Mar-2010

Period Length

9 Months

6 Months

3 Months

12 Months

9 Months

UpdateType/Date

Updated Normal
31-Mar-2011

Updated Normal
31-Dec-2010

Updated Normal
30-Sep-2010

Updated Normal
30-Jun-2010

Updated Normal
31-Mar-2010

Filed Currency

MYR

MYR

MYR

MYR

MYR

Exchange Rate (Period Average)

3.106731

3.135144

3.155953

3.385057

3.431818

 

 

 

 

 

 

    Operating Activities

10.3

9.1

4.6

10.9

0.9

Cash from Operating Activities

10.3

9.1

4.6

10.9

0.9

 

 

 

 

 

 

    Investing Activities

8.2

8.9

10.8

-6.1

-10.0

Cash from Investing Activities

8.2

8.9

10.8

-6.1

-10.0

 

 

 

 

 

 

    Financing Activities

-11.9

-10.6

-9.1

-6.8

12.2

Cash from Financing Activities

-11.9

-10.6

-9.1

-6.8

12.2

 

 

 

 

 

 

Foreign Exchange Effects

0.0

0.0

0.0

0.0

0.0

Net Change in Cash

6.6

7.4

6.3

-1.9

3.1

 

 

 

 

 

 

Cash-Beginning of Period

-5.9

-5.9

-5.7

-3.6

-3.5

Cash-Ending of Period

0.7

1.5

0.6

-5.5

-0.4

    Cash Interest Paid

-

-

-

5.6

-

    Cash Taxes Paid

-

-

-

1.2

-

 

 

 

 

Geographic Segments

Financials in: As Reported (mil)

Annual

 

 

 

External Revenue   USD (mil)

 

30-Jun-10

30-Jun-09

30-Jun-08

30-Jun-07

30-Jun-06

Asia

34.3

31.8 %

28.8

40.7 %

28.2

43.5 %

28.0

53.3 %

26.4

67.2 %

Africa

6.8

6.3 %

8.3

11.7 %

8.8

13.6 %

6.1

11.7 %

5.9

15.1 %

North America/South America

3.9

3.6 %

3.7

5.3 %

7.5

11.6 %

3.7

7.1 %

2.4

6.1 %

Europe

62.7

58.1 %

29.8

42.2 %

20.2

31.2 %

14.6

27.8 %

4.5

11.4 %

Pacific-Oceania

0.2

0.2 %

0.1

0.1 %

0.1

0.1 %

0.1

0.1 %

0.0

0.1 %

Segment Total

107.9

100 %

70.7

100 %

64.8

100 %

52.5

100 %

39.3

100 %

Consolidated Total

107.9

100 %

70.7

100 %

64.8

100 %

52.5

100 %

39.3

100 %

Exchange Rate: MYR to USD

3.385057

 

3.515259

 

3.315347

 

3.556314

 

3.731642

 

Total Revenue   USD (mil)

 

30-Jun-10

30-Jun-09

30-Jun-08

30-Jun-07

30-Jun-06

Asia

34.3

31.8 %

28.8

40.7 %

28.2

43.5 %

28.0

53.3 %

26.4

67.2 %

Africa

6.8

6.3 %

8.3

11.7 %

8.8

13.6 %

6.1

11.7 %

5.9

15.1 %

North America/South America

3.9

3.6 %

3.7

5.3 %

7.5

11.6 %

3.7

7.1 %

2.4

6.1 %

Europe

62.7

58.1 %

29.8

42.2 %

20.2

31.2 %

14.6

27.8 %

4.5

11.4 %

Pacific-Oceania

0.2

0.2 %

0.1

0.1 %

0.1

0.1 %

0.1

0.1 %

0.0

0.1 %

Segment Total

107.9

100 %

70.7

100 %

64.8

100 %

52.5

100 %

39.3

100 %

Consolidated Total

107.9

100 %

70.7

100 %

64.8

100 %

52.5

100 %

39.3

100 %

Exchange Rate: MYR to USD

3.385057

 

3.515259

 

3.315347

 

3.556314

 

3.731642

 

 

Total Assets   USD (mil)

 

30-Jun-10

30-Jun-09

30-Jun-08

30-Jun-07

30-Jun-06

Asia

171.3

99.2 %

193.7

99.9 %

189.8

100 %

117.2

100 %

75.2

100 %

Africa

0.0

0 %

0.0

0 %

0.0

0 %

0.0

0 %

0.0

0 %

North America/South America

1.3

0.8 %

0.2

0.1 %

0.0

0 %

0.0

0 %

0.0

0 %

Europe

0.0

0 %

0.0

0 %

0.0

0 %

0.0

0 %

0.0

0 %

Pacific-Oceania

0.0

0 %

0.0

0 %

0.0

0 %

0.0

0 %

0.0

0 %

Segment Total

172.6

100 %

193.9

100 %

189.8

100 %

117.2

100 %

75.2

100 %

Consolidated Total

172.6

100 %

193.9

100 %

189.8

100 %

117.2

100 %

75.2

100 %

Exchange Rate: MYR to USD

3.237500

 

3.515000

 

3.267500

 

3.452500

 

3.674500

 

Purchase of Fixed Assets   USD (mil)

 

30-Jun-10

30-Jun-09

30-Jun-08

30-Jun-07

30-Jun-06

Asia

1.2

55.2 %

7.5

100 %

44.7

100 %

26.6

100 %

18.8

100 %

Africa

0.0

0 %

0.0

0 %

0.0

0 %

0.0

0 %

0.0

0 %

North America/South America

1.0

44.8 %

0.0

0 %

0.0

0 %

0.0

0 %

0.0

0 %

Europe

0.0

0 %

0.0

0 %

0.0

0 %

0.0

0 %

0.0

0 %

Pacific-Oceania

0.0

0 %

0.0

0 %

0.0

0 %

0.0

0 %

-

-

Segment Total

2.2

100 %

7.5

100 %

44.7

100 %

26.6

100 %

18.8

100 %

Consolidated Total

2.2

100 %

7.5

100 %

44.7

100 %

26.6

100 %

18.8

100 %

Exchange Rate: MYR to USD

3.385057

 

3.515259

 

3.315347

 

3.556314

 

3.731642

 

 

 

Hovid Berhad

 

Perak, Malaysia, Tel: 60-5-5060690, URL: http://www.hovid.com/

 

Business Segments

Financials in: As Reported (mil)

Annual

 

 

 

External Revenue   USD (mil)

 

30-Jun-10

30-Jun-09

30-Jun-08

30-Jun-07

30-Jun-06

Pharmaceutical

36.4

33.8 %

32.0

45.3 %

33.1

51 %

26.5

50.4 %

23.3

59.2 %

Phytonutrient

71.5

66.2 %

38.7

54.7 %

31.7

49 %

26.1

49.6 %

16.0

40.8 %

Segment Total

107.9

100 %

70.7

100 %

64.8

100 %

52.5

100 %

39.3

100 %

Elimination

0.0

0 %

0.0

0 %

0.0

0 %

0.0

0 %

0.0

0 %

Consolidated Total

107.9

100 %

70.7

100 %

64.8

100 %

52.5

100 %

39.3

100 %

Exchange Rate: MYR to USD

3.385057

 

3.515259

 

3.315347

 

3.556314

 

3.731642

 

Intersegment Revenue   USD (mil)

 

30-Jun-10

30-Jun-09

30-Jun-08

30-Jun-07

30-Jun-06

Pharmaceutical

14.8

97.6 %

10.3

96.7 %

10.8

97.8 %

7.7

96.2 %

7.1

96.7 %

Phytonutrient

0.4

2.4 %

0.4

3.3 %

0.2

2.2 %

0.3

3.8 %

0.2

3.3 %

Segment Total

15.2

100 %

10.6

100 %

11.1

100 %

8.0

100 %

7.3

100 %

Elimination

-15.2

-100 %

-10.6

-100 %

-11.1

-100 %

-8.0

-100 %

-7.3

-100 %

Consolidated Total

0.0

0 %

0.0

0 %

0.0

0 %

0.0

0 %

0.0

0 %

Exchange Rate: MYR to USD

3.385057

 

3.515259

 

3.315347

 

3.556314

 

3.731642

 

 

Total Revenue   USD (mil)

 

30-Jun-10

30-Jun-09

30-Jun-08

30-Jun-07

30-Jun-06

Pharmaceutical

51.2

41.6 %

42.3

52 %

43.9

57.9 %

34.1

56.4 %

30.4

65.1 %

Phytonutrient

71.8

58.4 %

39.1

48 %

31.9

42.1 %

26.4

43.6 %

16.3

34.9 %

Segment Total

123.0

100 %

81.4

100 %

75.8

100 %

60.5

100 %

46.6

100 %

Elimination

-15.2

-12.3 %

-10.6

-13.1 %

-11.1

-14.6 %

-8.0

-13.2 %

-7.3

-15.7 %

Consolidated Total

107.9

87.7 %

70.7

86.9 %

64.8

85.4 %

52.5

86.8 %

39.3

84.3 %

Exchange Rate: MYR to USD

3.385057

 

3.515259

 

3.315347

 

3.556314

 

3.731642

 

Other Unusual Expense (Income)   USD (mil)

 

30-Jun-10

30-Jun-09

Pharmaceutical

-1.5

28.3 %

-0.7

100 %

Phytonutrient

-3.8

71.7 %

0.0

0 %

Segment Total

-5.3

100 %

-0.7

100 %

Elimination

0.0

0 %

0.0

0 %

Consolidated Total

-5.3

100 %

-0.7

100 %

Exchange Rate: MYR to USD

3.385057

 

3.515259

 

 

Depreciation   USD (mil)

 

30-Jun-10

30-Jun-09

30-Jun-08

30-Jun-07

30-Jun-06

Pharmaceutical

1.5

21.7 %

1.4

18.7 %

1.3

34.3 %

1.1

35.9 %

1.1

53.9 %

Phytonutrient

5.4

78.3 %

5.9

81.3 %

2.5

65.7 %

1.9

64.1 %

0.9

46.1 %

Segment Total

6.8

100 %

7.3

100 %

3.9

100 %

2.9

100 %

2.0

100 %

Elimination

0.0

0 %

0.0

0 %

0.0

0 %

0.0

0 %

0.0

0 %

Consolidated Total

6.8

100 %

7.3

100 %

3.9

100 %

2.9

100 %

2.0

100 %

Exchange Rate: MYR to USD

3.385057

 

3.515259

 

3.315347

 

3.556314

 

3.731642

 

Operating Income/Loss   USD (mil)

 

30-Jun-10

30-Jun-09

30-Jun-08

Pharmaceutical

5.4

-22.6 %

5.0

211.7 %

5.1

65.7 %

Phytonutrient

-29.3

122.6 %

-2.6

-111.7 %

2.7

34.3 %

Segment Total

-23.9

100 %

2.4

100 %

7.8

100 %

Consolidated Total

-23.9

100 %

2.4

100 %

7.8

100 %

Exchange Rate: MYR to USD

3.385057

 

3.515259

 

3.315347

 

 

Operating Margin (%)  

 

30-Jun-10

30-Jun-09

30-Jun-08

Pharmaceutical

10.5

-

11.8

-

11.7

-

Phytonutrient

-40.8

-

-6.7

-

8.4

-

Segment Total

-19.5

-

2.9

-

10.3

-

Consolidated Total

-22.2

-

3.3

-

12.1

-

Interest Expense - Operating   USD (mil)

 

30-Jun-10

30-Jun-09

30-Jun-08

Pharmaceutical

0.6

11.6 %

0.7

18.3 %

0.6

30.7 %

Phytonutrient

4.3

88.4 %

2.9

81.7 %

1.3

69.3 %

Segment Total

4.9

100 %

3.6

100 %

1.8

100 %

Consolidated Total

4.9

100 %

3.6

100 %

1.8

100 %

Exchange Rate: MYR to USD

3.385057

 

3.515259

 

3.315347

 

 

Income Before Tax   USD (mil)

 

30-Jun-10

30-Jun-09

30-Jun-08

30-Jun-07

Pharmaceutical

4.8

-16.7 %

4.3

-358.5 %

4.6

76.4 %

3.9

40 %

Phytonutrient

-33.7

116.7 %

-5.5

458.5 %

1.4

23.6 %

5.9

60 %

Segment Total

-28.9

100 %

-1.2

100 %

6.0

100 %

9.9

100 %

Consolidated Total

-28.9

100 %

-1.2

100 %

6.0

100 %

9.9

100 %

Exchange Rate: MYR to USD

3.385057

 

3.515259

 

3.315347

 

3.556314

 

Pre-Tax Margin (%)  

 

30-Jun-10

30-Jun-09

30-Jun-08

30-Jun-07

Pharmaceutical

9.4

-

10.2

-

10.5

-

11.6

-

Phytonutrient

-46.9

-

-14.2

-

4.4

-

22.4

-

Segment Total

-23.5

-

-1.5

-

7.9

-

16.3

-

Consolidated Total

-26.7

-

-1.7

-

9.3

-

18.8

-

 

Total Income Tax   USD (mil)

 

30-Jun-10

30-Jun-09

30-Jun-08

Pharmaceutical

1.2

-78.6 %

-1.0

136.9 %

-1.0

209.3 %

Phytonutrient

-2.7

178.6 %

0.3

-36.9 %

0.5

-109.3 %

Segment Total

-1.5

100 %

-0.7

100 %

-0.5

100 %

Consolidated Total

-1.5

100 %

-0.7

100 %

-0.5

100 %

Exchange Rate: MYR to USD

3.385057

 

3.515259

 

3.315347

 

Income After Tax   USD (mil)

 

30-Jun-10

30-Jun-09

30-Jun-08

30-Jun-07

Pharmaceutical

3.6

-13.3 %

3.3

-171.1 %

3.5

64.4 %

3.5

42.7 %

Phytonutrient

-31.0

113.3 %

-5.3

271.1 %

2.0

35.6 %

4.7

57.3 %

Segment Total

-27.4

100 %

-1.9

100 %

5.5

100 %

8.2

100 %

Consolidated Total

-27.4

100 %

-1.9

100 %

5.5

100 %

8.2

100 %

Exchange Rate: MYR to USD

3.385057

 

3.515259

 

3.315347

 

3.556314

 

 

Net Profit Margin (%)  

 

30-Jun-10

30-Jun-09

30-Jun-08

30-Jun-07

Pharmaceutical

7.1

-

7.9

-

8.1

-

10.2

-

Phytonutrient

-43.2

-

-13.5

-

6.2

-

17.8

-

Segment Total

-22.2

-

-2.4

-

7.3

-

13.5

-

Consolidated Total

-25.4

-

-2.7

-

8.5

-

15.6

-

Total Assets   USD (mil)

 

30-Jun-10

30-Jun-09

30-Jun-08

30-Jun-07

30-Jun-06

Pharmaceutical

55.8

32.4 %

50.6

26.1 %

49.1

25.9 %

40.8

34.9 %

35.9

47.9 %

Phytonutrient

116.2

67.6 %

143.2

73.9 %

140.7

74.1 %

76.2

65.1 %

39.1

52.1 %

Segment Total

172.0

100 %

193.8

100 %

189.8

100 %

117.0

100 %

74.9

100 %

Unallocated Amount

0.0

0 %

0.0

0 %

0.0

0 %

0.2

0.2 %

0.3

0.4 %

Consolidated Total

172.0

100 %

193.9

100 %

189.8

100 %

117.2

100.2 %

75.2

100.4 %

Exchange Rate: MYR to USD

3.237500

 

3.515000

 

3.267500

 

3.452500

 

3.674500

 

 

Operating Return on Assets (%)  

 

30-Jun-10

30-Jun-09

30-Jun-08

Pharmaceutical

10.1

-

9.8

-

10.6

-

Phytonutrient

-26.4

-

-1.8

-

1.9

-

Segment Total

-14.6

-

1.2

-

4.2

-

Consolidated Total

-14.6

-

1.2

-

4.2

-

Total Liabilities   USD (mil)

 

30-Jun-10

30-Jun-09

30-Jun-08

30-Jun-07

30-Jun-06

Pharmaceutical

33.4

25.9 %

22.9

17.3 %

21.4

16.8 %

14.7

23.6 %

14.0

44.7 %

Phytonutrient

95.5

74.1 %

109.4

82.7 %

106.2

83.2 %

47.7

76.4 %

17.3

55.3 %

Segment Total

128.9

100 %

132.4

100 %

127.7

100 %

62.4

100 %

31.3

100 %

Unallocated Amount

4.0

3.1 %

5.9

4.5 %

5.0

3.9 %

5.0

8.1 %

3.4

10.8 %

Consolidated Total

132.9

103.1 %

138.3

104.5 %

132.6

103.9 %

67.5

108.1 %

34.7

110.8 %

Exchange Rate: MYR to USD

3.237500

 

3.515000

 

3.267500

 

3.452500

 

3.674500

 

 

Purchase of Fixed Assets   USD (mil)

 

30-Jun-10

30-Jun-09

30-Jun-08

30-Jun-07

30-Jun-06

Pharmaceutical

1.6

73.2 %

1.0

13.2 %

4.0

8.9 %

2.3

8.5 %

2.0

10.6 %

Phytonutrient

0.6

26.8 %

6.5

86.8 %

40.7

91.1 %

24.3

91.5 %

16.8

89.4 %

Segment Total

2.2

100 %

7.5

100 %

44.7

100 %

26.6

100 %

18.8

100 %

Elimination

0.0

0 %

0.0

0 %

0.0

0 %

0.0

0 %

0.0

0 %

Consolidated Total

2.2

100 %

7.5

100 %

44.7

100 %

26.6

100 %

18.8

100 %

Exchange Rate: MYR to USD

3.385057

 

3.515259

 

3.315347

 

3.556314

 

3.731642

 

 

 

 

Business Segments

Financials in: As Reported (mil)

 

Interim

 

 

External Revenue   USD (mil)

 

31-Mar-11

31-Dec-10

30-Sep-10

30-Jun-10

31-Mar-10

Pharmaceutical

12.2

100 %

12.6

100 %

10.8

80.5 %

10.5

39.1 %

9.3

29.4 %

Phytonutrient

0.0

0 %

0.0

0 %

2.6

19.5 %

16.3

60.9 %

22.4

70.6 %

Segment Total

12.2

100 %

12.6

100 %

13.4

100 %

26.8

100 %

31.7

100 %

Consolidated Total

12.2

100 %

12.6

100 %

13.4

100 %

26.8

100 %

31.7

100 %

Exchange Rate: MYR to USD

3.048714

 

3.113817

 

3.155953

 

3.242957

 

3.372797

 

Total Revenue   USD (mil)

 

31-Mar-11

31-Dec-10

30-Sep-10

30-Jun-10

31-Mar-10

Pharmaceutical

12.2

100 %

12.6

100 %

10.8

80.5 %

10.5

39.1 %

9.3

29.4 %

Phytonutrient

0.0

0 %

0.0

0 %

2.6

19.5 %

16.3

60.9 %

22.4

70.6 %

Segment Total

12.2

100 %

12.6

100 %

13.4

100 %

26.8

100 %

31.7

100 %

Consolidated Total

12.2

100 %

12.6

100 %

13.4

100 %

26.8

100 %

31.7

100 %

Exchange Rate: MYR to USD

3.048714

 

3.113817

 

3.155953

 

3.242957

 

3.372797

 

 

Income Before Tax   USD (mil)

 

31-Mar-11

31-Dec-10

30-Sep-10

30-Jun-10

31-Mar-10

Pharmaceutical

1.7

695.5 %

2.3

243.1 %

1.6

-122.5 %

1.2

-3.2 %

1.2

27 %

Phytonutrient

-1.5

-595.5 %

-1.3

-143.1 %

-2.9

222.5 %

-39.4

103.2 %

3.3

73 %

Segment Total

0.2

100 %

0.9

100 %

-1.3

100 %

-38.1

100 %

4.5

100 %

Consolidated Total

0.2

100 %

0.9

100 %

-1.3

100 %

-38.1

100 %

4.5

100 %

Exchange Rate: MYR to USD

3.048714

 

3.113817

 

3.155953

 

3.242957

 

3.372797

 

Pre-Tax Margin (%)  

 

31-Mar-11

31-Dec-10

30-Sep-10

30-Jun-10

31-Mar-10

Pharmaceutical

14.1

-

18.2

-

14.9

-

11.8

-

13.1

-

Phytonutrient

-

-

-

-

-111.8

-

-241.3

-

14.8

-

Segment Total

2.0

-

7.5

-

-9.8

-

-142.3

-

14.3

-

Consolidated Total

2.0

-

7.5

-

-9.8

-

-142.3

-

14.3

-

 

Income After Tax   USD (mil)

 

31-Mar-11

31-Dec-10

30-Sep-10

30-Jun-10

31-Mar-10

Pharmaceutical

1.1

-351.4 %

1.8

416.4 %

1.3

-79.2 %

0.7

-2.1 %

0.9

24 %

Phytonutrient

-1.5

451.4 %

-1.3

-316.4 %

-2.9

179.2 %

-35.8

102.1 %

2.9

76 %

Segment Total

-0.3

100 %

0.4

100 %

-1.6

100 %

-35.0

100 %

3.8

100 %

Consolidated Total

-0.3

100 %

0.4

100 %

-1.6

100 %

-35.0

100 %

3.8

100 %

Exchange Rate: MYR to USD

3.048714

 

3.113817

 

3.155953

 

3.242957

 

3.372797

 

Net Profit Margin (%)  

 

31-Mar-11

31-Dec-10

30-Sep-10

30-Jun-10

31-Mar-10

Pharmaceutical

9.4

-

14.1

-

12.0

-

7.1

-

9.8

-

Phytonutrient

-

-

-

-

-111.9

-

-219.3

-

12.9

-

Segment Total

-2.7

-

3.4

-

-12.2

-

-130.8

-

12.0

-

Consolidated Total

-2.7

-

3.4

-

-12.2

-

-130.8

-

12.0

-

 

 Bottom of Form

 

 

FOREIGN EXCHANGE RATES

 

Currency
Unit

Indian Rupees

US Dollar

1

Rs.50.28

UK Pound

1

Rs.80.08

Euro

1

Rs.68.44

 

 

RATING EXPLANATIONS

 

RATING

STATUS

 

 

PROPOSED CREDIT LINE

>86

Aaa

Possesses an extremely sound financial base with the strongest capability for timely payment of interest and principal sums

 

Unlimited

71-85

Aa

Possesses adequate working capital. No caution needed for credit transaction. It has above average (strong) capability for payment of interest and principal sums

 

Large

56-70

A

Financial & operational base are regarded healthy. General unfavourable factors will not cause fatal effect. Satisfactory capability for payment of interest and principal sums

 

Fairly Large

41-55

Ba

Overall operation is considered normal. Capable to meet normal commitments.

 

Satisfactory

26-40

B

Capability to overcome financial difficulties seems comparatively below average.

 

Small

11-25

Ca

Adverse factors are apparent. Repayment of interest and principal sums in default or expected to be in default upon maturity

 

Limited with full security

<10

C

Absolute credit risk exists. Caution needed to be exercised

 

 

Credit not recommended

--

NB

                                       New Business

 

--

 

This score serves as a reference to assess SC’s credit risk and to set the amount of credit to be extended. It is calculated from a composite of weighted scores obtained from each of the major sections of this report. The assessed factors and their relative weights (as indicated through %) are as follows:

 

Financial condition (40%)            Ownership background (20%)                 Payment record (10%)

Credit history (10%)                    Market trend (10%)                                Operational size (10%)

 

PRIVATE & CONFIDENTIAL : This information is provided to you at your request, you having employed MIPL for such purpose. You will use the information as aid only in determining the propriety of giving credit and generally as an aid to your business and for no other purpose. You will hold the information in strict confidence, and shall not reveal it or make it known to the subject persons, firms or corporations or to any other. MIPL does not warrant the correctness of the information as you hold it free of any liability whatsoever. You will be liable to and indemnify MIPL for any loss, damage or expense, occasioned by your breach or non observance of any one, or more of these conditions

This report is issued at your request without any risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL) or its officials.